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ABSTRACT 
Functional Signatures in Protein-protein Interaction and Their Impact on 
Signaling Pathways 
 
Yichuan Liu 
Aydin Tozeren Ph.D. 
 
Protein-protein interactions (PPIs) are the most fundamental biological processes 
at the molecular level. PPIs have been proved to be involved in pathologic 
mechanisms of many diseases. The experimental methods for testing the binding 
of PPIs are time-consuming and limited by analogs for many reactions. As a result, 
a computational model is necessary to predict PPIs and to explore the 
consequences of signal alterations in biological pathways. 
A score matrix selection model was built based on overrepresented signature 
combinations. The case study focused on phosphorylation, which is a well studied 
post-translational modification category. The signature pairs were extended to 
signature-string pairs because of the multiple binding sites of kinase/substring 
interactions. A hypergeometric test was applied to select the significant signals 
due to the multiple-multiple relationship between the proteins and the 
domains/motifs. The prediction result shows an extremely high specificity 
(~100% compared to random combinations in the human protein pool) and an 
acceptable sensitivity rate (>65%) according to 10-fold evaluations.  The score 
matrix model has then been extended to the user-defined-input software, named 
 ix
‘YiRen’. A group of PPIs related to transcription factors were evaluated in the test 
case.  
Since the signatures embedded in protein sequences effect signal strength and 
they could be applied as the predictors in PPIs, alterations of these signatures 
could lead to broken edges in biological networks. An SNP is a kind of sequence 
variation. It is the major cause of human genetic variations and plays a key role in 
personalized medicine. In the DA-SNP (Domain-altering SNP) model, the SNPs 
from a dbSNP database were filtered through the domain regions on human 
proteomes. The SNPs were selected if they altered the domain signal strength by 
more than 10%. Then the selected SNPs were checked through an OMIM 
database for SNP-disease mappings, while the SNP-corresponding proteins were 
checked through the protein-disease database in Human Protein Reference 
Database (HPRD). The altered domains then projected into significant signature 
vectors in PPI prediction and the broken edges in biological pathways. The model 
linked the phenotypes and the sequence variation together with functional units in 
order to provide potential explanations for the phenotypes. 
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 CHAPTER 1: OBJECTIVES AND OVERVIEW 
 
1.1 Transition stage for protein-protein interactions 
The transition stage for protein binding is a period for breaking old bonds and 
forming new ones [1-2]. The formation could physically change the shapes of the 
protein and alter the activation energy for the chemical processes [3]. The binding 
energy can be determined and provides the enzyme specificity for the catalysis 
process [2, 4]. The protein-protein interaction (PPI) processes in the transition 
stage are extremely important because in short period binding, they will 
dramatically change the formation of the target proteins, and then cause variations 
throughout the whole system [2]. Typical transition binding protein-protein 
interactions include phosphorylation and transcription factor activity. 
Phosphorylation is a typical catalysis process, which adds a phosphate (PO4) 
group to a protein [5]. The addition of the phosphate to Ser, Tyr, and Thr residues 
could cause significant differences in the protein 3D structure, if the modified site 
responds to critical regions [2]. Kinase phosphorylation processes have proven 
that they play a critical role in cancer research and drug development [6-7]. 
Transcription factors always combined with other proteins to enhance or inhibit 
the transcription biological processes [8]. In eukaryotes, many transcription 
factors do not bind to DNA directly, but directly interact with RNA polymerase 
[9], which leads to protein-protein interactions. Transcription factor activity is 
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important because it is involved in the development of organisms [10], such as 
sex-determined region Y regulations [11]. Transcription factor activity also 
responds to the environment via signals, such as changes in temperature [12] and 
oxygen levels [13]. 
 
1.2 Functional signatures and databases 
The functional signatures in the protein sequences can be categorized by protein 
domain structures and linear motifs. The protein domain is a part of the protein 
sequence and structure, which can evolve, function, and exist independently of the 
rest of the protein chain [14]. The length of the domains is variant from about 25 
amino acids to 500 amino acids, which are on the average of 100 amino acids 
long [15]. The longest domain unit is lipoxygenase-1, with 692 residues [16]. 
Protein domains often form functional units such as the calcium-binding EF hand 
domain of calmodulin [17].  Protein domains are often found in the protein 
primary sequence, secondary structure or tertiary structure. The database of 
protein domains, families and functional sites (PROSITE) [18] is a database 
containing the domain information in grammar forms for the domains in primary 
and secondary structures. Grammar forms indicate that the domain is represented 
by a regular expression (pattern) or a position weight matrix (profile). The search 
engine of PROSITE [19] can be downloaded and takes the primary sequence of 
the protein as inputs and returns the hits of the domains found in the definition 
database. The distributions of the PROSITE domains across the human protein 
sequences are not uniform with low entropy (Figure 1.1). 
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The tertiary structure (3D) of the protein domains is useful in defining 
protein/domain families. Molecular evolution gives rise to families of related 
proteins with a similar sequence and structure. However, sequence similarities can 
be extremely low between proteins that share the same structure [20]. The current 
3D database related to the protein 3D domains is the Protein Data Bank (PDB) 
[21], which contains over 45,000 experimentally determined protein structures. 
As shown in Figure 1.2, several examples illustrate the protein-protein binding 
complex involved in domain-domain or domain-motif interactions. The problem 
with the 3D structure is coverage and incomplete structures (fragments). The 
binding visualizations were done by ZDOCK [22]. 
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The motifs are sequence motifs and/or structural motifs. Sequence motifs are 
nucleotide or amino-acid sequence patterns that are widespread and have a 
biological significance [14]. The sequence motifs are distinguished from 
structural motifs by way of the proteins. The structural motifs are formed by the 
three dimensional arrangement of amino acids, which may not be adjacent [14]. 
Compared to the domains that have multiple levels of structures, protein motifs 
are more linear, and the size of the motifs are relatively small compared to the 
domains (3~12 amino acids) [23]. The motif dictionaries that were applied to the 
present study are the PROSITE [18] and Eukaryotic Linear Motif (ELM) [24]. 
ELM treats motifs as regular expressions. Other famous functional unit databases 
related to motifs include Pfam [25] and Interpro [26].   
Another reason for choosing the domain/motif functional signature is that the 
interactions of any proteins can be converted to a network composed of functional 
signatures. In other words, functional signatures are generalized versions of amino 
acid sequences. An example is shown in Figure 1.3. The PPIs network relates to 
the protein kinase activities (PKA) that are defined by the Gene Ontology (GO) 
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database [27]. The network contains 1048 protein interactions with 497 proteins. 
The PPIs network is converted to the functional network, which then contains 187 
interactions that are related to 41 functional signatures. 
 
 1.3 Case study selections 
The protein interaction groups must satisfy the following conditions to be 
considered as ideal candidates. 1) The number of PPIs should be in the hundreds, 
since most statistical analysis methods prefer a large sample size. 2) The PPIs 
have proven that their bindings are involved with the domain/motif functional 
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signatures. Actually, there are many types of PPIs, and the domain-domain 
interactions (DDI) or domain-motif interactions (DMI) are only one group among 
different PPI types. 3) The PPIs relate to complex diseases, which provide 
significance to the project. In addition to the above requirements, it is better for 
the candidate groups to have experimental interaction databases to avoid biases 
and approximation errors during the selection process. 
Two case studies related to the transition binding were selected for the thesis: 
phosphorylation events and transcription factor activities. Phosphorylation events 
are a well-studied group of PPIs that relate to the domain/motif interactions 
(Figure 1.4) [14].  
 
The databases such as Post-Translational Modification (PTM) [28] and 
PhosphoELM [29] were the selections of experimentally determined 
phosphorylation events based on PubMed. These databases can be accessed and 
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downloaded directly from the Internet. Both databases contain enough PPI 
numbers for analysis. The PTM (2006 version) contains over 5,000 
phosphorylation events [28] and the PhosphoELM contain about 3,000 
phosphorylation events [29]. As mentioned in section 1.1, the phosphorylation 
events are considered as the causes/co-effectors in many genetic 
diseases/disorders. The kinases and their corresponding substrates were mapped 
into many prevalent diseases. Figure 1.5 shows the highlights of the kinase-
related diseases that are related to the AGC kinase group in the serine/theronine 
kinase category [30]. 
 
   Another candidate group of PPIs that is related to the transcription factor 
binding activities are selected for analysis. The transcription factors are the 
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proteins that bind to specific DNA sequences to control the transcription 
processes between DNA and RNA [31-32]. The transcription factors perform 
their functions alone or interact with other proteins to form protein complexes 
[33]. The formation of the protein complex can lead to promoting or blocking the 
RNA polymerase recruitment [34]. The transcription factors are associated with 
many diseases/disorders such as cancer [35-36], diabetes [37-38] and the neuro-
developmental disorders [39]. The transcription factors are very important in drug 
development. About 10% of the currently prescribed drugs are directly targeted to 
the transcription factors [40]. Unlike kinase/substrate proteins in the 
phosphorylation events, which contain protein binding domains, the transcription 
factor proteins contain the DNA-binding domains (DBD), the trans-activating 
domain (TAD) and the signal sensing domain (SSD) [31]. The TAD contains the 
binding sites for other proteins such as the transcription co-regulators [41].  
Currently, there are many databases that are related to the transcription factors. 
An example is the Eukaryotic transcription factors, their genomic DNA-binding 
sites and the DNA-binding profiles database (TRANSFAC) [42]. Unfortunately, 
the TRANSFAC database only contains the transcription factors and their DNA 
targets, not the protein binding partners. In this project, PPIs related to the 
transcription factor activities were selected from the Human Protein Reference 
Database (HPRD) [28, 43] and are filtered by Gene Ontology (GO) [27]. 
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1.4 Current methods for PPI predictions 
It is difficult to verify the transition binding activities experimentally due to the 
short period of their stages [2]. As a result, some indirect methods are applied to 
observe the changes in the transition stages. One of them is transition state analog 
testing. The transition state analogs are stable molecules that bind to enzymes 
more tightly than substrates [44-45]. The binding could cause different 
observations in the catalysis results, if the analogs are properly designed. The 
limitation of the experiments is that the analogs cannot perfectly mimic the 
transition stage [45]. In addition to the experimental methods, computational 
methods were applied to test the transition binding activities. Many prediction 
methods were developed over time, including predictions based on the physico-
chemical properties of the protein primary structures [46], Gene Ontology (GO) 
annotations [47], 3D-structures [48-49], and domain/motif interactions [50-52]. 
Research in PPIs suggests that the protein networks can be explained by 
functional unit interactions, and many researchers have tried to explore the 
signatures that are critical in the interaction networks.  
 
1.4.1 Primary structure and associated information 
PPI prediction methods that are based on the protein primary structures are the 
simplest and the most straightforward applications. Most of the primary structures 
are highly accurate and are available through the National Center for 
Biotechnology Information (NCBI) [53].  
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One of these methods was developed by Bock and his colleagues. The 
prediction processes were based on the Support Vector Machine (SVM), which 
generates a representation of non-linear mapping from residue sequence to protein 
fold space [46]. In other words, the representations of each protein interaction 
(called feature vectors) were applied to the non-linear kernel to differentiate the 
properties of the interactions. The feature vectors of SVM contain the residue 
properties such as the charge, the hydrophobicity and the surface extension 
parameters. The control group was generated by the random selections from the 
DIP database [54] since the databases of the non-interacting proteins are not 
readily available [46]. The machine learning process of the data is 2-fold, which 
means the ratio of the training data and the testing data is 1:1. The results from the 
SVM process are binary, which indicates the two proteins either bind to each 
other or they do not.      
The accuracy of this method is still considerably high among PPI prediction 
methods after nine years. The usage of the physicochemical properties provides 
useful information in the prediction processes because the false positives are 
removed. However, the requirements for physicochemical information make the 
method difficult to extend as a global approach. The number of PPIs is small in 
the prediction (around 4,000). The major limitation of the method is that the 
predictions cannot be made if the PPIs do not contain their corresponding 
physicochemical information. 
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1.4.2 Gene Ontology (GO)  
Scientists have tried to develop computational models that do not only depend on 
the protein sequence information. Wu and her colleagues developed a model 
solely based on the Gene Ontology (GO) annotations for the yeast protein-protein 
interactions [47]. 
The essential algorithm of the method is that the model measures the similarities 
between the two Gene Ontology (GO) terms with a relative specificity semantic 
relation (RSS) score. Prior to the real application, the GO terms were filtered if 
the biological processes or the cell locations were unknown. Since the GO 
database is constructed as a connected graph, the pathways from the GO term i to 
the GO term j are not unique for many cases. The algorithm chooses the shortest 
pathway and separates them into the three cases. The RSS is measured by three 
parameters: α, β and γ. The α parameter measures the specificity of MRCA (most 
recent common ancestor) for the two GO terms, which are according to the 
graphic structures.  The β parameter measures the relative generality of the GO 
terms. The generality of a term is defined as the minimum distance between the 
terms and all of the leaf terms from it. The γ parameter measures the local 
distances between two terms relative to the MRCA.  Based on the three 
parameters, the RSS value for the given GO terms i and j are defined from the 
formula in the paper.  
The protein pairs were divided into three categories based on the RSS value: 
high confidence group, medium confidence group and low confidence group. The 
authors then constructed the networks that were based on the gold standard. The 
 
 12
positive data consists of 40,753 interactions among 2,259 proteins [47]. The 
evaluations were performed from the mapping in the MIP complexes database 
and 35% of the complexes were identified as interconnected.  
 
1.4.3 Geometric simulations for binding interfaces 
The proteins interacted with each other with the 3D structures during real 
biological processes. The large experimental 3D structure databases provided 
potential possibilities to characterize the binding interfaces. Bahadur and his 
colleagues generated a model that relies on crystal-packing interfaces in terms of 
size,  shape and packing density [49].  
The crystallized structures were extracted from the PDB database (Protein 
Database Bank) [21]. Two parameters that are related to the interfaces were 
considered: the size and the shape. The size was calculated as the sum of SASA 
(solvent accessible surface area) for the different subunits, minus the SASA of the 
complexes. In addition to the size of the interface, the shape of the interface is 
another significant feature vector. The term “planarity” is used as a measure of the 
flatness for the interface curves. “Circularity” refers to the calculation of the ratio 
of the lengths in the principal axes of the least squares plane that penetrates the 
atoms at the interface.  A circularity score equal to one means the interface is 
close to a circular shape. “Shape complementarity” is the measure for the 
interfacial packing of the protein complexes [49]. For the prediction of actual real 
processes, the chemical compositions of the PPI interface and water molecules 
were also taken into account. 
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The major advantage of 3D methods is that the geometric simulation processes 
exclude many false positives. These false positives could not be removed from the 
linear protein sequence models. However, the trade-off is that the coverage is 
limited by the number of protein 3D crystallized structures. Another issue is 
protein 3D structures are dynamically changed in the biological processes [21]. 
Existing 3D structures do not guarantee that the structures in actual protein 
binding process maintain the functions. 
 
1.4.4 Functional signatures 
3D crystallized structures require large amounts of time and labor, and therefore 
some scientists have tried to explore “grammar” embedding in the 
primary/secondary/tertiary structures of proteins. Domains usually are defined as 
a conserved region whose functions are involved in the protein interaction process. 
Motifs are very short residue sites, but play an important role in mediating or 
regulating protein interactions. In 2005, Albercht and his colleagues decomposed 
the protein networks into domain-domain interactions (DDIs) and showed that 
protein interaction processes can be demonstrated by functional signatures 
embedded in the protein primary structure [55].  
Chang and his colleagues developed a model that focuses on the Cyclin-
dependent kinase Cdc28 (Cdk1) in yeast [56]. The paper defined the Cdk motif 
regular expression. The essential method algorithm revolves around is clustering 
the yeast proteins based on the number of occurrences of motif sites. The clusters 
were then compared with randomly generated mock proteome groups. A cut-off 
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value was generated by the minimized sum of the standard errors, which were 
calculated as the mean value of all compared ratios between yeast and mock. 
Proteins above the cut-off were considered as Cdk substrate sites. 
Guo and his colleagues developed a computational model for the motif site 
discovery. Motifs are very short pattern signatures, and are therefore hard to 
define by experimental observations. The authors aligned the interacted protein 
sequences and compared them with the established motif databases [57]. The 
proteins were abandoned if they were not in the same cell components or they did 
not contain any motifs.  To calculate the over-represented motifs, the authors used 
two different statistical analyses: the one-tailed exact binomial test and the one-
tailed Fisher’s exact test. The binomial test compares the positive data with the 
random background based on binomial distribution. Fisher’s test uses a 
hypergeometric distribution to explore rare motifs. Another accomplishment of 
this paper is the discussions related to negative data. The machine learning 
process in the evaluations requires negative datasets, but non-interaction protein 
databases were not available. The paper discusses about four different types of 
negative datasets: random protein pairs, protein pairs separated by cellular 
locations, the protein pairs that are unrelated in the biological processes and 
protein pairs involved in different biological processes that are in a low or median 
confidence level of same cellular locations.  
Functional signatures provide the potential candidate binding sites for the 
protein interactions.  Schelhorn and his colleagues developed an integrative 
approach to associate the protein interaction regions based on the previously 
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defined databases. The essential algorithm is to build a probability model that fits 
the protein interaction networks [51]. The probabilistic method maximizes the 
expected likelihood of observed PPIs. The parameter θ represents the probability 
of two regions that interact with each other. It has been defined as the 
corresponding maximum likelihood estimation parameter in the expectation 
maximization algorithm. The method provided the results of all the possible 
combinations of the Pfam and the ELM signatures with high confidence.  
Predictions by functional signatures are very popular in the current research 
field for two reasons: 1) Most of the function signatures do not require a 3D 
crystallized structure (although the algorithms can use the 3D structure to remove 
the frequent occurrences), and 2) the functional signatures are defined globally, 
which means different organisms could be tested in the same model.    
 
1.5 SNP altered signatures 
PPI prediction methods are useful in exploring protein mechanisms. Functional 
signatures play a critical role in interaction processes, which has been illustrated 
in previous results. Compared to predicting the PPIs phenomenon, it is more 
interesting to explore the potential consequences for biological networks, if the 
signatures are altered. The resulting observations can link the sequence alterations 
to the phenotypes, such as for disease or disorder status.  
     A single-nucleotide polymorphism (SNP) is a DNA sequence variation for one 
nucleotide at a certain frequency of the genome [58]. About 90% of human 
genetic variations are caused by SNPs [59], and these variations can affect 
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developments of human diseases and responses to pathogens, chemicals, drugs, 
vaccines, and other agents [60-61]. The results from the HAPMAP project 
provided the information of genetic variances from different populations; as a 
result SNPs, are not only considered a key to personalized medicine, but also as 
an indicator of the essential differences across populations [62]. However, there 
are 1.42 million SNPs defined from human genome in 2001 [63], and currently, 
over 10 millions SNPs are defined in the dbSNP database from NCBI [64], with 
only about 4,000 SNPs mapped to disease/disorder status [65]. In order words, 
compared to the identification of new SNPs, mapping the known SNPs to their 
corresponding functions are more effective. Due to the large number of existing 
SNPs, it is impossible to map all SNPs into their genotypes experimentally. As a 
result, the computational model mapping between the SNPs and genotypes, 
especially complex diseases, are required.  
Non-synonymous SNPs alter the amino acid in protein sequences; therefore, 
these SNPs have the potential to change the grammar/signatures that are 
embedded in the protein sequences (Figure 1.6). The silent/active signature could 
effect the PPI if the PPI relies on the domains or motifs, which would cause the 
connections to collapse in biological networks. In other words, the SNP-disease 
mapping model could provide potential explanations for many diseases related to 
complex biological pathways. 
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1.6 Current methods in SNP-phenotype association 
Currently, there are two major categories that are related to SNP-genotype 
association methods. The first category focuses on non-synonymous SNPs, which 
change the critical amino acids in a protein sequence, such as binding sites 
defined in the SWALL database for PolyPhen [66], binding motifs from 
TRANSFAC for target SNP [67], and the sites related to protein stability and 
cellular processing in the SNP-effect [68]. These methods are used to select 
functional SNPs by determining whether the direct alterations present for the 
critical amino acids (e.g., phosphorylation site). In addition to the false positive 
problem, the major challenge of these methods is false negatives, which could not 
explain the fact that certain site changes do not effect genotypes, since the 
mapping result is a Boolean expression (either modifying the site or not). The 
second category is based on the computational intelligence model [69]. The SNP-
disease data are constructed in different data structures, such as a logic tree (GA, 
GP) [70-71], neural networks (GPNN) [72], and the ensemble learning approach 
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(ELAS) [73]. All models use complex data structures to define the SNP-disease 
association that could achieve good accuracy computationally. The results are 
also confirmed in clinical data (e.g., Parkinson disease). However, these statistical 
models emphasize the correlations between the SNPs and the diseases found via 
observation, which does not provide a potential biological insight in terms of the 
correlations and/or causations. 
 
1.6.1 Critical amino acid alterations 
One group of the SNP-disease association methods focuses on the critical amino 
acid changes, which affect the binding or structure stabilities. The assumption of 
the methods is straightforward and the methods mainly focus on the non-
synonymous SNPs. These methods (e.g. PolyPhen [66]) use the defined 
physiochemical databases as dictionaries and check whether the changes for the 
amino acid would effect the critical sites, such as ligands and other polypeptides. 
The dictionary for the PolyPhen method is SWALL database [74]. The feature 
tables in SWALL include DISULFID, THIOLEST, THIOETH bond, BINDING, 
ACT_SITE, LIPID, METAL or MOD_RES. PolyPhen also maps the substitution 
sites to the known protein 3D structures. The mapping of an amino acid 
replacement to a known 3D structure reveals whether the replacement is likely to 
destroy the hydrophobic core, electrostatic interactions, interactions with ligands, 
or other important protein features. The application uses the BLAST query to scan 
the PDB [21] and PQS. A similar approach called SNPeffect [68] defines the 
SNP-disease associations by protein folding/stability, functional sites and cellular 
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locations. The folding/stability are estimated by FoldX [[75] and TANGO [76]. 
The database of functional sites is based on the Catalytic Site Atlas (CSA) [77], 
which documents enzyme active sites and catalytic residues in enzymes with 3D 
structures. The cellular localization is determined by PA-subcellular [78] and 
Psort II [79]. 
 
1.6.2 Data-mining/computational intelligence methods 
In addition to predictions in the first category, another group of methods that are 
based on data-mining/computational intelligence was developed in the SNP-
disease association. The rationale behind these methods is that the methods should 
not introduce any human effectors to the system, such as the biological 
information from external resources. Let the data indicate via different data 
structures and statistical analysis [69]. Popular examples of statistical methods 
and machine learning models in SNP-disease study include multiple linear 
regressions, logistic-regression, Haplotype trend regression, logic regression, 
random forest, SVM, principal component analysis (PCA) and clustering methods. 
Both statistical analysis and machine learning models have been tried to find a 
minimum set of important SNPs that are related to the disease outcomes. 
However, machine learning models focus more on classification and prediction 
purpose instead of associate studies in the statistical analysis.  Recently developed 
approaches include GA [70], GP [71], GPNN [72] and ELAS [73]. 
The GA method categorizes the SNPs into blocks based on the score of the 
linkage disequilibrium (LD) and constructs logic trees consisting of Boolean 
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expressions based on these blocks. The logical trees are selected in each 
generation by using a marginal likelihood in a Bayesian regression framework. 
The GP method is closely related to the GA method but uses tree-based strategies 
to represent a solution for the problem instead of using a string of variables. A 
genetic programming neural network (GPNN) method was developed for 
detecting epistasis in the SNPs data.  Epistasis is the observation that the functions 
of one gene are modified by one or several other genes [80]. In other words, the 
GPNN method could detect gene-gene or gene-environment interactions. The 
GPNN method has been applied to real data analysis of Parkinson’s disease [72]. 
The Ensemble learning approach for the set association (ELAS) method detects a 
set of loci that predict disease/disorder status. The ELAS method searches the 
basic learner feature vectors at the beginning and combines the effects of these 
feature vectors for the SNP prediction. The simulation tests claim that the 
combination of the markers is more powerful than a single marker. Hubley 
presented an evolutionary algorithm for SNP selection. The method is based on 
the modified version of the strength Pareto algorithm, which is particularly suited 
for multiple objectives involved problems.  Other methods related to the 
evolutionary algorithm were also developed, such as GAs in modeling epistasis 
and evolutionary trees for haplotype fine mapping [81].  
Two major challenges exist for computational intelligence methods. The first 
challenge is the overfitting problem. Experimental data of SNP-disease 
associations contain noise due to genotyping errors, missing data and genetic 
heterogeneity. As a result, overfitting problems are inevitable. For example, GP is 
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no better than a simple random search when classification accuracy is used as the 
fitness function. However, if the pre-process was applied with expert knowledge, 
the GP performance was significantly improved [71]. The problem is that the pre-
processing steps violate the rule of the basic principle that no external effectors 
are allowed to be put into the system. The second potential problem is that the 
methods provide mappings or associations between the SNPs and the phenotypes, 
but offer no explanation of the results of the biological process. This fact leads to 
inconsistency of the simulations and real data. For example, Motsinger applied 
the ELAS method to large scale type-2 diabetes. ELAS identified 11 significant 
SNPs and none of them showed significant marginal effects [72].      
 
We merged the designs of both categories, and came up with a bioinformatics 
approach to predict SNP-disease correlations due to non-synonymous SNPs. The 
model uses protein sequence grammars as a statistical model and the SNP was 
selected based on the signal strength that is related to the protein structures or 
functional domain/motif [18]. The results were then mapped and checked through 
the human disease database at multiple biological levels, including the SNP level 
(OMIM) [65], protein level (HPRD disease database) [43], and biological 
pathway level (KEGG) for evaluations [82]. As a result, the predicted set 
provided a list of SNP-disease association terms, which provided the explanations. 
The domain-alter SNPs (DA-SNPs) predicted from the models are the potential 
targets or markers for further explorations in human diseases. 
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Chapter 2 introduces the bio-simulation model that constructs domain-domain 
networks from known phosphorylation events, including the prediction principles 
and the performance evaluations in the independent databases. Chapter 3 extends 
the model globally as a software tool and takes the transcription factor PPIs as a 
test case for evaluations. Chapter 4 introduces the model links of the SNP 
variations to the phenotypes based on grammar alterations of the functional 
regions, while the potential effects on biological networks are also explored.  
Chapter 5 includes the overview of the thesis and two topics for future work that 
are involved with linkage disequilibrium (LD) and cross-species talk. 
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CHAPTER 2: MODULAR COMPOSTION PREDICTS 
KINASE/SUBSTRATE INTERACTIONS. 
 
 
Note: This chapter is adapted from a paper submitted to BMC Bioinformatics and 
the requested revisions have been submitted. 
 
2.1 Summary 
Phosphorylation events direct the flow of signals and metabolites along cellular 
protein networks. Current annotations of kinase-substrate binding events are far 
from complete. In this study, we scanned the entire human protein sequences 
using the PROSITE domain annotation tool to identify patterns of domain 
composition in kinases and their substrates. We identified statistically enriched 
pairs of strings of domains (signature pairs) in kinase-substrate couples presented 
in the 2006 version of the PTM database. The signature pairs enriched in kinase – 
substrate binding interactions turned out to be highly specific to kinase subtypes. 
The resulting list of signature pairs predicted kinase-substrate interactions in a 
validation dataset not used in learning with high statistical accuracy. The method 
presented here produces predictions of protein phosphorylation events with high 
accuracy and coverage. Our method can be used in expanding the currently 
available drafts of cell signaling pathways and thus will be an important tool in 
the development of combination drug therapies targeting complex diseases. 
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2.2 Background 
Transient interactions of proteins with other proteins, such as those that occur 
during phosphorylation events, comprise a fundamental element of signal 
processing in living cells [14]. Protein kinases constitute one of the largest 
families of signaling proteins in eukaryotic cells [30]. Currently, there are more 
than 500 known protein kinases in the human genome [83]. A phosphorylated 
amino acid distinguishes itself from the unmodified residue by having a large 
hydrophilic group with increased hydrogen-bonding, hydration and salt-bridge 
formation capability. Such modifications often result in switches and altered lines 
of connections in signaling and metabolic pathways of living cells [14]. 
Phosphorylation binding interactions are important downstream in gene 
expression pathways in the binding of transcription factors to their substrate 
proteins [84].     
Transient interactions between proteins often require multiple sites of physical 
connection and may even require a third party protein such as an adopter protein. 
Catalytic phosphorylation events at active sites is facilitated either by the use of 
protein recognition modules or the adaptation of docking interactions [85]. Recent 
structural data indicates that specificity of binding between a kinase and a 
substrate does not necessarily arise from the active site, but from the substrate and 
the specific docking interactions [86].  Globular domain – motif interactions 
accompany active site interactions in the binding of tyrosine kinases to their 
substrates. Large numbers of such globular domain/linear motif interactions have 
already been associated with protein-protein interactions (PPIs).  Web tools such 
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as PROSITE [19], Pfam [87], PRINTS [88], ProDom [89], and InterPro [90] can 
be used to annotate the globular domains and larger linear motifs on the sequence 
of any given protein. Similarly, the web tool ELM [91] annotates on protein 
sequences large numbers of linear motifs known to be involved in protein 
interactions.  Some of these motifs may play important roles in virus-host 
interactions via a mechanism for a hijacking function [92-93].  
Known annotations of domain-motif interactions on protein partners often result 
in the prediction of large numbers of false positives in PPIs [92]. It is also 
becoming clear that selectivity of docking sites in MAPK kinase, along with the 
catalytic motif, is an important player in identifying PPIs [94].  An accurate 
method of PPI prediction based on interactions of short linear motifs on one 
protein with large globular domains on the protein pair is yet to be developed [95].  
Computational prediction of PPIs from primary sequences of proteins poses a 
number of other challenges to overcome, including the noise in the training PPI 
data, lack of a true negative training set, as well as problems associated with 3D 
experimental and molecular modeling of proteins in potentially binding 
configurations [96]. PPI prediction methods developed in the last decade include 
methods based on sequence homology [97], feature vectors and machine learning 
methodology [46], association studies [98], and knowledge guided inference of 
domain-domain interactions from incomplete PPI networks [99]. Computational 
studies focusing on extracting domain signature pairs associated with PPIs have 
utilized yeast datasets [98] or datasets spanning across species [99].  
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The success achieved in computational association of domain signature pairs 
with experimentally verified PPIs in these aforementioned studies prompted us to 
investigate signature pair/PPI associations in phosphorylation events within the 
human proteome. We asked the question of whether modular composition of 
proteins (kinase and their substrates), combined with a database of a known PPI, 
could be sufficient in a statistical enrichment procedure to predict known PPIs not 
used in the training. The choice of domains as features for predicting PPIs made 
sense because modular composition of proteins provides insights into their 
interaction with up and downstream proteins in cell signaling circuits [14, 85].  
In addressing this question, we used the Post Translational Modification (PTM) 
database 2006 edition containing 5,602 PPIs to identify statistically enriched 
signature pairs in kinase/substrate binding. Our ten-to-one and two-to-one 
learning and testing procedures produced receiver operator characteristic curves 
reflecting excellent accuracy in the identification of phosphorylation events. 
Additional verification included the use of PPIs in the PTM 2009 edition and in 
other databases not included in PTM [43, 100-101]. Our bioinformatics analysis 
uncovered sets of domain clusters that are specifically enriched in various kinases 
and kinase substrates. Moreover, we showed that pairs of such domain clusters 
bridge kinase and kinase substrates with high specificity and sensitivity.  
The computational space in our model is large compared to other approaches 
focusing only on the domain annotation of proteins known to be interacting with 
each other. In the present study we scanned the entire proteome for domain 
annotation in order to develop background sets of randomly generated virtual 
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protein pairs to be used in the statistical enrichment of domains in protein subsets. 
Another feature specific to our method is the consideration of strings of domains 
as signatures for binding predictions. This assumption facilitated us to consider 
binding events between proteins involving multiple sets of domains.  Results 
produced by our method achieved better PPI prediction accuracy in 
phosphorylation on average when compared to other presently available 
computational methods for PPIs. Our study illustrates the dominance of a 
grammar based on interacting domain signature pairs in the language of post 
modification interactions between proteins in the human proteome.  
 
2.3 Method 
2.3.1 PPI data for phosphorylation events 
The learning dataset on kinase/substrate binding was downloaded from the Post 
Translational Modification database (PTM), version 2006 [28]. The dataset 
contained 5,602 phosphorylation events between 272 kinases and 1,432 kinase 
substrates. The independent testing datasets consisted of phosphorylation events 
not recorded in the PTM 2006 database but recorded in the PTM 2009 database 
[101], the Human Protein Reference Database (HPRD) [28], and the Biological 
General Repository for Interaction Datasets (BioGRID) [100]. Predictions of our 
model were used to match phosphorylated proteins in the PhosphoELM database 
[91] with candidate targeting kinases for further experimental verification.  
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2.3.2 Scanning proteins for PROSITE domains and their enrichment in 
protein subgroups 
 
A database of protein domains, families and functional sites named PROSITE [18] 
was downloaded to our laboratory’s Blade Center. In this set up, the search engine 
for PROSITE took protein FASTA sequences as inputs and returned hits of 
PROSITE domains (D) as outputs. Human protein sequences from the NCBI 
Gene Bank were scanned and a column matrix indicating the presence (1) and 
absence (0) of domains was assigned for each human protein. The dimension of 
these domain column matrices was equal to the number of domains (2,102) in the 
PROSITE Database.  
 
2.3.3 Statistical enrichment of domains in protein subgroups 
Statistical enrichment of domains in protein subgroups (target groups) was 
performed with respect to a control (background) group made of the entire protein 
kinase group. Domain column matrices were determined for each member of a 
target group, and these matrices were summed up over the membership of the 
subgroup. Next, a set of proteins of the same number as the target group was 
selected randomly from the background group and the corresponding sum domain 
column matrix was computed. This operation was repeated 10,000 times and the p 
value for enrichment was computed by the fraction of times the background group 
had more domains of a given identity than the target group. A list of domains 
(domain clusters) enriched in a kinase- or substrate subtype was identified as the 
list of signatures that were enriched in the target group, a kinase- or substrate 
subtype.  
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2.3.4 Score matrix for signature pairs in PPIs 
A score matrix was constructed for selecting signature pairs strongly associated 
with known PPIs in tyrosine- and serine/threonine phosphorylation subgroups. 
Specifically, we wanted to identify signature pairs (such as A-B) such that the 
presence of signature A in protein K and signature B in protein L would predict 
with high confidence a PPI between K and L. For this purpose, for the known PPI 
interactions in the learning dataset (EPPI), we generated a score matrix whose 
rows and columns identified the enriched signatures in tyrosine and 
serine/threonine kinases (TK, S/TK) and their substrates (TKB, S/TKB). Each 
element of the matrix corresponded to the number of EPPIs for which a signature 
pair (A-B) was present in the opposing proteins of the pair. Another score matrix 
for virtual PPI and VPPI (background) was generated by randomly pairing 
proteins from the learning dataset, in effect creating VPPI interactions equal in 
number to all of the possible protein combinations from the kinase and substrate 
proteins in the PPI set. The p value for the signature pair enrichment in a given 
PPI subgroup was computed using the hypergeometric test in the R Project for 
Statistical Computing, based on the scores summed from the learning set and the 
background set. The resulting signature pairs were ranked according to their p 
value, with the one corresponding to the lowest p value ranked highest. The 
highest p value used as the cut-off in the analysis was p = 0.001.  
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2.3.5 Prediction accuracy for string pairs 
The signature pairs thus identified via statistical enrichment were used to predict 
new PPI events. A protein pair was considered as undergoing phosphorylation 
interaction if it expressed at least one of the signature pairs determined by the 
enrichment analysis. Consider a protein pair (L, K) that is associated with a 
statistically enriched signature pair (A-B). An assumption that the presence of A-
B means the presence of a phosphorylation PPI between L and K (PPPI) may lead 
to false positives. The prediction accuracy was evaluated by computing the 
probability that the match between predicted and experimental PPI sets have 
occurred randomly. Consider that there are N VPPI events that can be generated 
randomly from n kinases and m kinase substrates. Among the N VPPI, M have 
already been annotated as EPPIs. Let the signature pair A-B predict Y number of 
PPPIs, W of which have been verified as EPPIs. The hypergeometric test then 
tests the probability of randomly choosing at least W EPPIs by selecting Y PPPIs 
out of a possible N VPPI. The lower the p value, the higher the accuracy of the 
PPI prediction method presented in this study.  
 
2.3.6 Sensitivity, specificity, precision, and recall  
In addition to p values, prediction accuracy was evaluated using parameters for 
defining accuracy and coverage: Specificity (Sp) and Sensitivity (Se).  Let TP, TN, 
FP, and FN represent, respectively, the true positives, true negatives, false 
positives, and false negatives determined with the use of known PPIs in the 
predicted set. Sp and Se were defined as follows: 
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Sp = TN/(TN + FP), Se = TP/(TP + FN) 
    The higher the value of Sp, the lower the error for assuming the PPIs between L 
and K are based on the presence of the enriched signature pair (A-B). Parameter 
Se is a measure of the coverage, namely the size of the PPI pool potentially 
predicted by A-B.  
We also used precision and recall to evaluate the statistical enrichment of 
experimental PPIs in our predicted PPI set. Precision (Pr) was defined as TP/(TP 
+ FP). Recall (Re) is the same as the sensitivity parameter Se.  
 
2.3.7 Cross validation with independent datasets 
We used training and testing sets at 2-fold and 10-fold cross validation to test the 
accuracy of our predictions in 100 iterations using statistical enrichment with p 
values varying from zero to one [102]. After each set of training and testing, we 
determined the specificity and sensitivity. We plotted the receiver operating 
characteristics (ROC) curve using the average values of specificity and sensitivity 
over 100 iterations. The area under the ROC curve (AUC) quantified the 
likelihood that one can identify a kinase-substrate interaction using the method 
described above.  
In addition, we used multiple validation processes to evaluate the performance 
of our model. The first process was to check the accuracy of the enriched 
signature pairs in predicting PPI among the random protein pairs derived from 
proteins in the learning data set. A p value representing the probability of 
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randomly generated prediction was computed for the PPIs predicted by each 
signature pair by using the hypergeometric test.  
Next, we compared the PPI predictions based on the PTM 2006 learning 
database with PPIs not present in the PTM 2006 database, but present in the PTM 
2009 database and in two other databases (HPRD, BioGrid). We identified the 
phosphorylation PPIs in the HPRD and BioGrid databases as those PPI made of a 
kinase and a substrate partner of the same type (tyrosine or serine/threonine) listed 
in Gene Ontology [103]. For each comparison, we computed the number of PPIs 
predicted, the number of PPIs matched, and the maximum number of virtual PPIs 
that could be generated using the testing PPI dataset. These numbers yielded p 
values for random predictions using the hypergeometric test.  
 
2.3.8 Comparison with other computational models  
We tested the accuracy of PPI predictions of the present model with two 
previously published domain based methods: correlated sequence-signature 
markers (CSSM) [98] and the knowledge-guided inference of domain-domain 
interactions (K-GIDDI) [99]. Using the algorithms and data presented in these 
papers, we identified the enriched domain pair signatures and the resulting 
numbers of predicted PPIs, as well as the number of matched PPIs (matching 
already annotated PPIs) within the randomly generated PPI set from the PTM 
2006 database as well as the validation datasets used for our model.  We used the 
hypergeometric test, sensitivity, and specificity as described above to identify the 
accuracy of prediction.   
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2.4 Results 
2.4.1 PROSITE domains enriched in kinase and their substrates 
Our computations showed that kinases and their substrates express statistically 
enriched protein domains that are largely subtype specific. We scanned the human 
protein sequences in the NCBI database via the PROSITE web tool and identified 
the domains/signatures expressed on their sequences (Figure 2.1 A). We then used 
statistical enrichment as described in the methods section to identify those 
domains enriched in a target kinase (substrate) subtype group against all kinase 
(kinase substrates) with enrichment p < 0.05. This enrichment procedure was 
carried out for the ten kinase subtypes described in Manning’s paper. Figure 2.1B 
shows that domains enriched in a certain kinase (substrate) subtype are largely 
mutually exclusive to the subtype under consideration. The subtype specificity of 
domains expressed by kinase and substrates reduced drastically the number of 
domain signature pairs that needed to be considered for PPI prediction.  
Next, we considered the groups of enriched domains expressed by kinases and 
their substrates, grouped in two major subgroups: tyrosine and serine/threonine 
kinases (substrates). Many of these proteins expressed more than one subtype-
specific enriched domain, as shown in Figure 2.2. In other words, not only 
domains but domain strings were also enriched in tyrosine and serine/threonine 
kinase groups and their substrates. Therefore, each such enriched string of 
domains could be considered to constitute a signature. This observation is 
consistent with the known preferred mode of interaction between tyrosine kinase 
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and their substrates (domain-motif interactions) versus the docking site 
interactions employed in serine/theorine kinases [85]. 
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2.4.2 Score matrices for identifying domain signature sets enriched in known 
kinase protein interactions 
 
A score matrix in our analysis has m rows and n columns, with each row 
corresponding to one of the m-enriched signatures (domains or string of domains) 
in a kinase category (TK or S/TK). Each column indicates one of the n-enriched 
signatures in the corresponding substrate category (TKB or S/TKB) (Figure 2.2).   
 
    Elements of the target PPIs score matrix show the number of times a signature 
pair is found in PPI in the PTM 2006 database. Elements of the virtual PPI score 
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matrix show similarly the numbers of correlated signatures in this much larger 
pool of randomly generated protein pairs from the PTM 2006 database proteins in 
PPIs. Let M be the number of PPIs under consideration and let N be the number 
of randomly generated protein pairs (including the actual PPI pairs), then a 
hypergeometric test can be used to estimate the probability of a PPI score matrix 
element having the value m by chance when the corresponding value in a virtual 
PPI score matrix is n. The negative logarithms of these p values for the correlated 
signature pairs are shown in Figure 2.3 on the score matrix heat maps for TK PPI 
(left) and S/TK PPI (right). Note that the smaller the p value, the darker the matrix 
element is corresponding to a signature pair.   
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    The signature pairs presented predicted nearly 80 percent of the PPIs used in 
identifying the correlated signature pairs. Note that, on average, each signature 
pair is correlated with ten PPIs, suggesting that domain compositions of proteins 
involved in phosphorylation are indicative of their potential for binding. The p 
value shown in Table 2.1 for the training part of this case indicates the efficiency 
of our score matrix approach in correlating signature pairs with phosphorylation 
PPI events.  
Table 2.1 Accuracy and coverage of the present approach for predicting kinase - 
substrate interactions. EPPI: Number of Experimental PPI; PPPI: Number of 
predicted PPIs; MPPI: Number of matches between PPPIs and EPPPIs; VPPIs: 
Number of Virtual PPI used in p value computations. Also shown is the prediction 
coverage and accuracy of two previously published approaches (CSSM, K-
GIDDI).  
 
    Training       Testing       
    PTM  2006 HPRD    BioGrid   PTM  2009 
    TK S/TK TK S/TK TK S/TK TK S/TK 
  EPPI 886 2925 137 199 111 166 33 237 
Data Kinase 56 176 60 104 41 67 15 61 
  Substrate 274 881 32 44 26 44 21 90 
  VPPI 15344 155056 1920 4576 1066 2948 315 5490 
  PPPI 1132 7133 43 204 36 69 27 193 
  MPPI 617 1876 18 26 17 15 6 16 
Present  p value  0 0 9 E-12 1.3E-7 1E-9 7E-7 0.014 0.0038 
  Se 69.6 64.1 13.14 13.07 15.32 0.04 18.18 6.75 
  Sp  96.6 95.4 97.76 95.54 96.62 97.66 91.43 96.48 
  PPPI 14496 122975 763 1411 433 836 234 4462 
  MPPI 826 2815 84 67 64 53 26 160 
CSSM p value  0.9416 0 3.8E-8 0.0096 4.33E-5 0.128 0.204 1 
  Se 93.23 96.24 61.31 33.67 57.66 31.93 78.79 67.51 
  Sp  5.44 20.69 60.26 69.17 59.38 71.64 25.71 18.72 
  PPPI 1491 1557 117 75 88 68 33 65 
  MPPI 206 42 19 6 17 5 2 11 
KGIDDI p value  0 0.0098 1.3E-4 0.0432 0.0025 0.181 0.7 0.0002 
  Se 23.25 1.44 13.87 3.02 15.32 3.01 6.06 4.64 
  Sp  90.28 99 93.9 98.36 91.74 97.69 89.52 98.81 
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2.4.3 Validation with independent experimental datasets 
Approximately 70 percent of known kinase-substrate interactions occurred 
between proteins with at least one annotated PROSITE domain on their primary 
sequence.  For cross validation, we used the kinase-substrate pair list in the PTM 
2006 database and took its subset made of protein couples, with both proteins 
expressing at least one annotated PROSITE domain. This restriction was 
necessary since our prediction method is based on the existence of certain domain 
pairs (signature pairs) in interacting proteins. As described in the methods section, 
we used 10-fold and 2-fold cross validation in 100 iterations and generated 
receiver operating characteristic (ROC) curves for predicting tyrosine kinase and 
serine/threonine kinase interactions (Figure 2.3B). The figure indicates excellent 
accuracy at 10-fold cross validation and slightly lower accuracy in 2-fold cross 
validation. The areas under the ROC curves (AUC) for these cases are reported in 
the figure.     
Next, we compared our predicted PPI set with those phosphorylation PPI sets 
that had not been used in our statistical enrichment processes. Three PPI 
databases, BioGrid, HPRD, and PTM 2009, contained hundreds of 
kinase/substrate phosphorylation events, as shown in Table 2.1 for the testing part. 
We used the signature pairs listed in Appendix B to predict PPI events among the 
proteins in the PPI events shown in Table 2.1 for the testing set. The p values for 
the match between our predictions and the known PPI events not used in our 
enrichment procedures ranged from 9*10-12 to 7*10-7 for PPIs presented in the 
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HPRD and BioGrid databases, whereas we had higher but still significant p values 
when predicting  the PTM 2009 database.   
Next, we compared the experimental data shown in Table 2.1 with the 
corresponding predictions that could be made using the domain based methods 
recently published (CSSM & K-GIDDI) [98-99]. These comparisons yielded p 
values that were larger than the ones for our method. In particular, the p values 
showed no significance for the model CSSM predicting the PTM 2009 database 
and the serine/threonine binding data from the BioGrid database. The reason why 
our model yielded better results than CSSM could be due to our grammar 
differentiating between proteins with different domain string expression. Another 
reason might be our use of randomly generated background PPI databases in our 
enrichment method, rather than an analytical equation based only on data for PPIs. 
Note also that the CSSM model was for the yeast proteome, and we used not their 
published results, but generated PPI predictions using their procedure here for 
comparison with experimental data for the human proteome.  
K-GIDDI simulation also yielded higher p values than our method when 
compared with the human protein interactive data shown in Table 2.1. The 
comparison might be unfavorable to K-GIDDI, since the model incorporates PPI 
events from multiple species during the training phase and therefore might miss 
some PPI events specific to humans. Nevertheless, the fact that all three of these 
approaches gave statistically significant predictions for at least the HPRD 
database indicates the validity of domain based approaches in predicting 
phosphorylation events. Sensitivity and specificity parameters were also 
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computed for the three approaches across different datasets. Present study shows 
same the accuracy level of specificity as K-GIDDI and better coverage, while 
CSSM shows much better coverage, but much less specificity.  
Overall, our approach predicts 8,837 kinase-substrate interactions from a pool 
of 186,715 virtual interactions and matches 2,591 PPIs out of the experimentally 
verified 4,694 PPIs. The p value for the match is zero and precision and recall are 
equal to 0.293 and 0.552, respectively. Predictions for tyrosine kinase mediated 
phosphorylation PPIs is better in terms of precision than those PPIs involving 
serine-theronine kinases (Table 2.2), but, nevertheless, both predictions match 
experimental data with a zero p value for a random match.   
 
             Table 2.2 Efficiency of the present score matrix enrichment in matching known   
             Phosphorylation PPI.   
 
  PPPI EPPI MPPI VPPI Precision Recall p value 
Overall 8837 4694 2591 186715 29.3 55.2 0 
TK 1238 1167 658 18645 53.2 56.4 0 
S/TK 7599 3527 1933 168070 25.4 54.8 0 
 
 
2.4.4 Matching kinase with substrates in expanding previously annotated 
cellular pathways 
 
Nearly 30 percent of our predictions match experimentally verified 
phosphorylation PPIs. We screened the substrates in the remaining 70 percent for 
their presence in the PhosphoELM [12] database. We found that an additional 30 
percent of our predictions involved kinase substrates for which kinase partners are 
yet to be identified. For this reason, we wanted to see if our PPI prediction 
 
 42
method could be used to revise and possibly expand previously annotated cellular 
pathways involved in signaling. Consider, for example, the KEGG MAPK 
signaling pathway [104] showing a chain of phosphorylation events starting at the 
cell surface and concluding with transcription factors that interact with DNA. A 
large number of the nodes in the figure are kinase substrates and our DDI based 
predictions of the corresponding kinases match with those in the KEGG pathway 
(Figure 2.4).  Nodes marked in red in the pathway are listed in PhosphoELM  [91] 
as kinase substrates with unknown kinase identity. Our predicted kinases for those 
nodes have been added to the KEGG diagram. Out of the 11 predicted 
kinase/substrate interactions added to the KEGG pathway, 6 appear in the HPRD 
or BioGrid databases, indicating that any expansions to previously established 
protein interactomes using our approach will likely be biologically relevant. 
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2.5 Discussion & Conclusion 
Binding interactions of proteins with other proteins are at the foundation of 
cellular networks. Phosphorylation is responsible for the flow of signals and 
metabolites along the protein pathways [96]. Dynamic binding interactions, such 
as those that occur in phosphorylation events, appear prominently in signaling 
pathways in health and in disease, including hypertension, diabetes, HIV infection, 
and cancer [30, 105]. Although kinases have long been considered as drug targets, 
compounds targeting kinases (kinase inhibitors and natural substances) have been 
found to be more promiscuous than originally anticipated, which can potentially 
lead to side effects [106]. It is important to identify potential phosphorylation 
partners of kinases in order to assess their range of impact on the flow of signals 
and metabolites along cellular pathways. Recent methods of mapping dynamic 
protein interactions in kinase signaling using live-cell fluorescence fluctuation 
spectroscopy and imaging have already produced promising results [107] and 
kinase morphisms have been directly linked to population subtypes in disease 
states [108]. These new experimental approaches will benefit from the ongoing 
efforts in predicting dynamic protein interactions based on existing data and 
learning/testing/validation approaches. Our study produces these types of 
computational prediction sets of protein-protein interactions for experimental 
validation.  
    We used large-scale bioinformatics databases and tools and developed a 
methodology for predicting phosphorylation binding events that are yet to be fully 
annotated. Our method benefits from the hypothesis and assumptions of the 
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previous computational methods of PPI prediction and specifically utilizes the 
concept of correlated sequence signatures as markers of protein-protein 
interaction developed by Sprinzak and Margalit (2001). The two new elements in 
our approach consist of (a) expanding the definition of a signature to strings of 
domains rather than a single domain and (b) the use of a background composed of 
a random pairing of kinases and substrates in the statistical processes for 
identifying signature pairs indicative of phosphorylation events. The first 
assumption is consistent with our observation that certain strings of domains are 
highly statistically enriched in kinase subtypes and their substrates compared to 
the rest of the kinase interactome. The second assumption, which was a 
requirement of statistical enrichment against highly differentiating background 
sets, allowed us to further reduce the set of correlated sequence signatures 
obtained solely on the data involving PPIs.  The list of signature pairs developed 
in the present study, when used in predicting kinase/substrate interactions in 
phosphorylation events, produced results that are largely matched with 
experimental data not used in statistical enrichments for signature identification. 
The p values associated with our predictions and their comparison to independent 
experimental data ranged from a low of E – 11 to 0.0038, depending on the kinase 
subtype and the database used for comparison.  
    Thousands of human proteins have been identified as undergoing 
phosphorylation binding interactions in the PhosphoELM database, but the 
identity of the kinases responsible for these phosphorylation events have yet to be 
quantified. Our method produced candidate kinases targeting these substrates. The 
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resulting list turned out to be consistent with literature not yet included into the 
PhosphoELM database. In all cases, the partnering between the substrates and the 
kinases predicted in this study can serve as a guide for kinase identification 
studies involving known kinase substrates. Another important use of our method 
will be in expanding and revising existing literature on cellular pathways 
decorated with phosphorylation events. Such revisions will be useful in 
identifying the consequences of small drug interventions on a kinase in terms of 
its interaction with immediate neighbors. Last but not least, our observation that 
domains expressed by kinase proteins and their substrates are largely subtype-
specific drastically reduces the upper bound for the number of experiments one 
has to conduct for quantifying a major subset of transient binding interactions 
between protein pairs associated with phosphorylation.  
    One important disadvantage of our method is the bias toward the discovery of 
PPIs with proteins having similar domain composition. This feature is also 
persistent in PPI prediction methods based on sequence homology. This tendency 
is observable in our prediction of new results included in PTM 2009 based on the 
PTM 2006 dataset. Although our match is statistically significant, the p values we 
get for this comparison is significantly larger than the comparison with  the 
HPRD and BioGrid database. It is expected that our methodology will pick up 
more PPI events correctly as we learn more about the protein sequence grammar 
that relates domain expression with protein-protein interaction patterns.  
    Protein phosphorylation events redirect and redistribute the flow of signals and 
metabolites in cellular pathways. Kinases that phosphorylate multiple substrates 
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have been favorable targets for drug development against many disease types. In 
this study, we developed a high throughput method that predicts potential binding 
partners for kinases using existing domain annotation tools and interactome 
databases for the human proteome. The method, when tested against independent 
databases, yields predictions with high statistical accuracy. Results indicate that 
domains expressed by any two proteins constitute a strong determinant of the 
potential for phosphorylation related binding interactions between them. Our 
expansion of the MAPK pathway using the prediction method outlined in the 
study presented results compatible with research literature. 
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CHAPTER 3: YiRen: A Prediction Tool for Protein Binding Interactions 
based on Functional Domain Pair Enrichement 
 
Note: This chapter is adapted from a paper and is waiting for final approval from 
my advisor for submission 
 
 
3.1 Summary 
Protein-protein interactions (PPIs) play a fundamental role in cell signaling and in 
response to external factors. Experimentally verified PPI events in the human 
proteome are like the tip of an iceberg as not a single PPI event has been assigned 
for more than half of the known human proteins.  A computational method 
predicting candidates for experimental studies on protein binding interactions 
would be of significant use if the method achieved low false positive discovery 
ratios. In this study, we introduce a new PPI prediction tool: YiRen. We have 
developed a tool package to predict potential PPI events based on primary 
sequences of proteins annotated for their functional domains. YiRen takes a user 
defined binary PPI set as a training set, generates a domain string pair enriched 
model called score matrix, then uses statistical enrichment analysis to extract 
enriched domain string pairs compared with a random background. YiRen has 
been tested in the PPI ontology related to phosphorylation and transcription factor 
activities and shows better performance across similar technologies in both PPI 
prediction accuracy and domain-domain interaction coverage. 
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3.2 Background 
Protein-protein interactions (PPI) play a fundamental role in biological processes 
spanning from signal transduction, and post translational modification to the 
assembly  of ribosomes and other protein machinery [109]. In the absence of a 
high  throughput experimental methodology for quantifying protein interactions, 
computational methods have been developed to see if a sequence and 3D structure 
of proteins could be used to predict the binding interactions between them [96, 
110]. These methods, some of them using machine learning techniques, present 
the opportunity to develop candidate interaction sets for experimental validation.  
Interactions between proteins often require multiple sites of physical connection 
and may even require a third party protein such as an adopter protein. Catalytic 
phosphorylation at active sites is facilitated either by the utilization of protein 
recognition modules or the adaptation of docking interactions [85]. Web tools 
such as PROSITE [111], Pfam [112], PRINTS [88], ProDom [89], and InterPro 
[26] can be used to annotate the globular domains and large linear motifs on the 
sequence of any given protein. Similarly, the web tool ELM [24] annotates on 
protein sequences large numbers of linear motifs known to be involved in protein 
interactions. The expression of proteins as a series of domains and motifs allows 
for elucidation of not only binary but also multi protein interactions.  
The potential for predicting protein binding interactions based on domain 
functional units has been under investigation [113]. This research has already 
demonstrated that the protein networks could be at least partially explained by 
domain/motif interactions enriched in protein binding interaction subtypes. This 
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study presents a software tool package, called “YiRen”, for the prediction of 
protein binding interactions based on the statistical enrichment of domain pairs in 
binding interaction subtypes. The software uses a set of user defined PPIs as a 
training set, extracting the domain feature vectors from a global domain database. 
The code allows for the determination of overrepresented patterns of domain 
combinations using a “score matrix” approach (Chapter 2). The user could use 
these patterns to predict new PPIs from their own pool of proteins of interest. The 
previous research indicated the overflow of false positives in protein binding 
interaction predictions [92]. The size of the set of PPI predictions presented by the 
tool depends on the level of accuracy specified and thus could be used to provide 
predictions with high specificity and low sensitivity, if so desired by the user. The 
code the tool is based on was used by us previously for predicting kinase/substrate 
interactions based on domain enrichment (Chapter 2), but it is presented in this 
study as a bioinformatics tool useful to predict transient interactions between 
proteins and creating protein networks from a specified group of proteins.   
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3.3 Implementations  
The flow chart shown in Figure 3.1 summarizes the process of predicting PPIs 
using YiRen.  The algorithm produced for this tool extracts a PROSITE domain 
expression from protein sequences, generates score matrices for training and 
testing against random backgrounds, conducts statistical enrichment analysis and 
predicts sets of new PPI events. To conduct the tasks shown in Figure 3.1, YiRen 
has been organized as a main script calling sub functional processes in a step-by-
step procedure.  
YiRen is activated for use when the user double clicks on  the “script.exe” file 
after downloading the tool package from the website 
http://code.google.com/p/tozerenlab/downloads/list and unzipping it.  A command 
window will show up and welcome information will appear. Then the query for 
the first user input appears. The user is required to type in the absolute pathway of 
PPI interaction files (human protein RefSeq ID required). Each PPI in the input 
file must be according to the format “proteinA + /tab + proteinB” (an example 
could be found in the “testCase” folder).  
After a pathway is correctly typed in as an input by the potential user, the tool 
maps the input proteins into the human protein database from the NCBI GenBank 
and extracts the PROSITE domains. A score matrix is generated for selecting 
domain signature string pairs strongly associated with the training PPIs. The tool 
identifies signature pairs (such as A-B) such that presence of signature A in 
protein K and signature B in protein L would predict with high confidence a PPI 
between K and L. A signature indicates a PROSITE domain or domain cluster. 
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The method described in detail in Chapter 2 is summarized as follows. For each 
training PPI interaction in the user input file, YiRen generates a score matrix 
whose rows and columns identify the enriched signatures. Each element of the 
matrix corresponds to the number of PPIs in the training set in which a signature 
pair (A-B) is present in opposing proteins of the pair. Another score matrix for 
virtual PPIs (control group) is generated by randomly pairing proteins from the 
training dataset. The p value for enrichment in a given PPI is computed using a 
hypergeometric test based on the scores summed from the training set and the 
background (control) set. The resulting signature pairs are ranked according to 
their p value, with the one corresponding to the lowest p value ranked highest. For 
an input file containing two thousand PPI events, the score matrix computation 
and domain string pair selection takes about 10 seconds on a desktop computer. A 
file name “pV_sorted” is generated in the folder for results. This file includes the 
domain strings sorted by a hypergeometric p value, a cumulative number of PPI 
coverage, sensitivity, specificity against the training set and the name (PROSTIE 
ID) of the corresponding domain strings.  
The decision rule used in YiRen for whether a protein pair is a PPI or not is as 
follows: if the protein pair contains at least one significant domain string pair for a 
given p value cutoff, it is considered as a PPI; otherwise, it is not. The second user 
input is in response to the query for the p value cut-off for prediction. After a float 
number (from 0~1) is typed for the p value, all of the domain string pairs having p 
values less than or equal to the cut-off are used to annotate new PPI events.  
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The third user input is in response to the query about the pool proteins among 
which new PPI events are to be predicted. If the user types ‘Y’, the fourth user 
input dialog appears asking for the pathway of the protein list (in RefSeq ID). If 
the user types ‘N’, the program takes whole human proteins as candidate pool for 
prediction. Because of the large number of a human protein pool (~37000) and its 
possible combinations (>1 billion protein pairs), this process will take hours to 
finish. A new set of predicted PPIs (in RefSeq ID) is generated based on the 
decision rule described above and a file name “prediction_PPI” will be located in 
the result folder. The command window will be close after all computations are 
completed. 
 
3.4 Results & Discussion 
The potential use of the tool is illustrated with protein binding predictions related 
to transcription factor activity. Prediction accuracy of the tool is compared with 
two other computational approaches also utilizing domain expression in the 
prediction of protein binding interactions. Transcription factor binding to other 
proteins initiates, enhances or inhibits the transcription biological processes [8]. In 
eukaryotes, many transcription factors do not bind to DNA directly, but interact 
with the RNA polymerase [9], resulting in multi-protein interactions.  
We used a subset of PPI related to transcription factor binding activity in the 
human protein reference database (HPRD) 2006 version as the input training 
dataset. We projected all PPI in HPRD on Gene Ontology Molecular Function 
level 4 transcription factor activity and took the subset of PPIs for which one 
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member of the PPIs belonged to this GO category.  The PPIs related to the same 
GO category in the HPRD 2009 version (but not in the 2006 version) were 
applied as a validation set. The validation results were cross-compared with two 
previously published domain based methods: correlated sequence-signature 
markers (CSSM) [98] and the knowledge-guided inference of domain-domain 
interactions (K-GIDDI) [99]. Results are shown in Table 3.1.  
 
            Table 3.1: Validation of YiRen prediction across independent PPI set with other  
            methods for 37 PPIs in the new 2009 version from 54 proteins pool. 
 
  YiRen CSSM k-GIDDI 
# predicted PPI 59 434 36 
# Matches 7 18 2 
p value 6.84E-05 0.0043 0.0605 
 
 
The p values for the match between our predictions and the known PPI events 
not used in our enrichment procedures is significant in predicting transcription 
factor activities in the HPRD 2009 version. The comparisons yielded higher p 
values for the two other models in the literature. In particular, the p values showed 
no significance (p value>0.05) for the model K-GIDDI predicting the HPRD 2009.  
The comparison might be unfavorable to K-GIDDI since the model 
incorporates PPI events from multiple species during the training phase and 
therefore might miss some PPI events specific to humans. Nevertheless, the fact 
that all three approaches gave statistically significant predictions for at least the 
HPRD database indicates the validity of domain based approaches in predicting 
events related to transcription binding activity.  
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In conclusion, the tool package YiRen can be used to identify candidate links 
among a given set of proteins creating a protein network based on the knowledge 
of domain pairings in known cases of protein binding interactions. Specific 
applications to phosphorylation (Chapter 2) and transcription binding activity 
indicates that predicted links between proteins are highly statistically enriched 
with links identified and verified experimentally. Our method is applicable not 
only to the discovery of protein binding pairs but also to the association of 
multiple proteins in a transient or stationary complex.     
 
3.5 Availability 
Project name: YiRen  
Project home page: http://code.google.com/p/tozerenlab/downloads/list, 
Operating system(s): Windows  
Programming language: Python 
Other requirements: Python 2.5  
License: none  
Restrictions of use by non-academics: contact authors for conditions 
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CHAPTER 4: DOMAIN ALTERING SNPS IN THE HUMAN PROTEOME 
AND THEIR IMPACT ON SIGNALING PATHWAYS 
 
 
Note: This chapter is adapted from a paper submitted to Biophysical Journal and 
is currently under review. 
 
 
4.1 Summary 
Single nucleotide polymorphisms (SNPs) constitute an important mode of genetic 
variations observed in the human genome. A small fraction of SNPs, about four 
thousand out of the ten million, has been associated with genetic disorders and 
complex diseases. The present study focuses on SNPs that fall on protein domains, 
3D structures that facilitate connectivity of proteins in cell signaling and 
metabolic pathways. We scanned the human proteome using the PROSITE web 
tool and identified proteins with SNP containing domains. We showed that SNPs 
that fall on protein domains are highly statistically enriched among SNPs linked 
to hereditary disorders and complex diseases. Proteins whose domains are 
dramatically altered by the presence of an SNP are even more likely to be present 
among proteins linked to hereditary disorders. Proteins with domain-altering 
SNPs comprise highly connected nodes in cellular pathways such as the focal 
adhesion, the axon guidance pathway and the autoimmune disease pathways. 
Statistical enrichment of domain/motif signatures in interacting protein pairs 
indicates extensive loss of connectivity of cell signaling pathways due to domain-
altering SNPs, potentially leading to hereditary disorders.  
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4.2 Background 
Hereditary disorders are often linked to rare mutations in the form of single 
nucleotide polymorphisms (SNPs) [114]. Evolutionary forces introduce many 
new variants into the human genome in each generation [58]. SNPs affect  the 
tendency to develop autism, diabetes, and cancer and impact immune response to 
pathogens, chemicals, drugs, and vaccines [59-61]. The HAPMAP project 
presents information concerning genetic variances among ethnic population 
subtypes thus implicating SNPs as key differences across population subtypes 
[62].  
More than ten million SNPs have been identified in the human genome [64]. 
SNPs that fall into coding or promoter regions of proteins comprise only a small 
fraction of the presently annotated SNPs. To date, nearly four thousand SNPs 
have been mapped to the disease/disorder status [65]. Genome-wide 
computational studies complement clinical studies correlating SNPs to disease. 
However, approaches based on statistics alone provide limited insights on how a 
genetic variation causes disease.  
Current methods for discovery of SNP-genotype linkages include those focusing 
on non-synonymous SNPs that alter functional motifs such as binding sites [66], 
DNA binding motifs [67] and sites related to protein stability and cellular 
processing [68]. Computational intelligence models [69] utilize logic tree [70-71], 
neural networks [72], an ensemble learning approach [72] or evolutionary 
algorithms [73] to discover correlations between SNPs and hereditary disorders 
and provide potential biological insight for the observed correlation and/or 
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causation. Overall, the aforementioned approaches have illustrated the potential 
use of computational system modeling in the discovery of links between disease 
and the genotype.  
This study focuses on a specific subset of human genotype-disease linkage, 
namely the annotation of SNPs that alter protein domains and thus potentially 
break bonds between interacting proteins in cell signaling pathways [14]. Protein 
domain structure is relatively flexible with respect to the amino acid sequence 
defining the domain, as illustrated by the domain annotation web tools such as 
Pfam [115] and PROSITE [18]. However, scanning proteins through these web 
tools, one can illustrate that even a single SNP could alter the structural 
configuration so extensively as to erase a domain from the structural composition 
of a given protein.  
In this study, we screened the human proteome for domain annotation using the 
PROSITE web tool [19]. We projected the previously annotated SNPs onto 
proteins and identified those SNPs with domain altering properties. The resulting 
set turned out to be highly statistically enriched among proteins linked to genetic 
disorders [18]. We annotated these proteins using a variety of bioinformatics 
databases and web tools and showed that proteins with domain altering SNPs 
crowd the protein networks involving focal adhesion, axon guidance, natural 
killer cell mediated cytotoxity, and neurotrophin signaling pathways. Our 
predictions of linkages broken in these pathways indicate severe reduction of 
connectivity in signaling pathways associated with complex diseases and 
hereditary disorders.  
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4.3 Method  
4.3.1 Discovery of domain-altering SNPs 
 
The human SNP database was downloaded from the NCBI dbSNP database [64]. 
dbSNP is an archive containing over 10 million human SNPs, and among them, 
63,899 missense SNPs. The SNPs were then projected onto corresponding human 
protein sequences from the NCBI GenBank. Peptide sequences of potentially 
SNP-containing proteins (in SNP-absent and SNP-containing forms) were 
screened for annotation of protein domains using PROSITE [18]. A domain with 
potential to contain a SNP was called D-SNPs.  
The PROSITE output for each sequence was in the form of a matrix with three 
columns, with the columns indicating (1) the ID number of the PROSITE domain, 
(2) the binary value identifying the presence or absence of a domain, and (3) the 
PROSITE matching score (MS) if the domain was expressed as a profile (position 
weight matrix) rather than expressed in the form of a pattern (regular expression). 
The second and the third columns of the output data allowed us to identify those 
SNPs that either removed a domain from the protein structure or drastically 
altered it when compared to sequences with and without the SNPs (DA-SNPs). If 
the PROSITE domain was defined as a regular expression, the second column 
was sufficient to identify whether the domain also existed in the presence of the 
SNP.  
For those domains expressed as a profile, we checked the third column for the 
value of the matching score parameter of the same protein with and without the 
SNP. We defined a domain distortion (DD) parameter as the ratio of the 
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difference in the matching score (due to the presence of the SNP) to the matching 
score of the sequence without the SNP. In our scans, DD varied from 0 to 0.3, 
which was the maximum domain distortion observed in our computations. 
Domains with DA-SNPs were defined as the sets of domains for which the 
sequence with SNPs no longer fits the regular expression, plus a set of profile 
domains with a finite DD value cut off in the presence of the SNPs.  
Examples of structural diagrams of proteins with DA-SNPs were obtained using 
the Protein Data Bank (PDB) [116] (for the case of no SNP) and SNPs3D [117] 
(with SNPs). The structures were aligned using YASARA [118] and the location 
of the SNP was marked with yellow. The lists of proteins with D-SNPs and DA-
SNPs were presented as inputs to DAVID Bioinformatics resources [119] and 
enriched KEGG pathway [120] profiles and Gene Ontology [103] categories at a 
p-value cut-off of 0.01. 
 
4.3.2 Bonds broken between a protein with a domain altering SNP and its 
neighbors in signaling pathways 
 
We used statistical enrichment to identify protein signatures (domains, motifs) 
most likely to be found among binding partners of the proteins containing 
domain-altering SNPs. We created a score matrix with rows indicating domains 
that can be altered by an SNP and columns indicating domains and motifs found 
in binding partners of proteins with domain altering SNPs. Each element of the 
score matrix represented the number of times a domain with an SNP was found 
associated with a signature (domain, motif) on a binding partner. The web tool 
ELM [23] was used to annotate linear motifs on proteins. We then created random 
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protein binding partners to proteins with SNP containing domains and created a 
score matrix as a background for statistical enrichment analysis. We used the 
hypergeometric test to identify those domains/motifs most likely to signal a 
protein-protein interaction involving domains with DA-SNPs.  This procedure 
allowed us to identify signature pairs (such as A-B) such that the presence of 
signature A (domain with an SNP) in protein K and signature B in protein L 
would predict a binding interaction between K and L. The link A-B is a candidate 
for a bond potentially broken due to the presence of the domain altering SNP in a 
cellular pathway.  To eliminate possible false positives in the estimates of bonds 
broken, we required the signature pair (A-B) to be either in the DOMINE [121] 
database or previously annotated as a domain-motif pair as predictive of binding 
interactions between two proteins [92].  
 
4.4 Results 
Our computations show that proteins with SNPs in one or more of its domains are 
significantly more likely to be associated with human disorders. Out of the 63,899 
SNPs in the coding regions of proteins, 1,782 SNPs are present in the Online 
Mendelian Inheritance in Man (OMIM) database [65]. A total of 12,965 SNPs fall 
into protein domains, and 592 proteins with domain SNPs are associated with a 
disease or disorder in OMIM. If this intersection to have occurred by a random 
event, it has a zero p value, indicating that SNPs in the domain regions of proteins 
are highly correlated to genetic disorders and complex diseases.  This observation 
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is consistent with the important functions protein domains play in establishing 
connectivity among proteins in cell signaling pathways [14].  
Among proteins with domain SNPs, those with domain-altering SNPs are even 
more likely to be associated with disorder/disease. Domain-altering SNPs 
discovered in our PROSITE screening method consists of two subsets. The first 
subset consists of SNPs the sequence no longer satisfies in the regular expression 
for the domain. The second subset is composed of domains defined as a profile 
above a prescribed domain distortion (DD) parameter cutoff. An example of a 
domain with DA-SNP is p53. Figure 4.1 shows the 3D structure of TP53 in the 
presence and absence of a DA-SNP (SNP rs28934571), as well as the poor 
alignment of these structures due to the presence of the SNP.  This SNP occurs at 
sequence position 249 and causes losses of hydrogen bonds and salt bridge bonds.  
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We evaluated the statistical enrichment of the domain altering SNPs in the 
OMIM Database as a function of the DD cutoff, as shown in Table 4.1. In all 
cases, the p value < 0.05 indicates significance of enrichment with respect to all 
domains with SNPs. The list of proteins with domain-altering SNPs in which both 
the protein and the SNP were linked to the same disease/disorder is presented in 
Table 4.2 for DD > 0.10. The table covers proteins associated with a variety of 
diseases ranging from pancreatic cancer, epilepsy, and to carpal tunnel syndrome.   
Proteins with domain-altering SNPs crowd GO molecular function categories 
involving calcium ion binding, adenyl ribonucleotide binding, protein kinase 
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activity, and endopeptidase activity at DD > 0.10. The DD cutoff of 0.10 
corresponds to 598 domain-altering SNPs present in 505 proteins. Among these 
proteins, 242 had at least one known binding partner in the Human Protein 
Reference Database (HPRD) [43]. The GO level 5 molecular function gene 
ontology categories shown in Figure 4.2A are statistically enriched with proteins 
with domain altering SNPs (p < 0.01). The list of GO categories shown in the 
figure indicates that proteins with domain-altering SNPs comprise key nodes in 
protein networks; their loss of connectivity would likely have a significant effect 
on cellular signal transduction.  
 
Table 4.1: Statistical enrichment of domain altering SNPs in the OMIM 
database.  
 
Each row gives the overall statistics of domain-altering SNPs and the p value for 
statistical enrichment in OMIM at a given domain distortion (DD) parameter 
cutoff. The p values are computed based on hypergeometric test.  
 
# D-SNP # D-SNP & OMIM DD cut-off # SNPs OMIM match p value 
12965 801 0.05 1152 75 0.0444 
    0.10 598 46 0.0197 
    0.15 497 40 0.016 
    0.20 451 35 0.028 
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Table 4.2:  List of proteins with domain altering SNPs (DD > 0.1) for which both 
the SNP and the protein were previously associated in the literature with a 
hereditary disorder or complex disease. The columns in the table present the gene 
symbol, the SNP ID, the name of the domain with the SNP, whether is DD 
violation (yes) or violation of regular expression (no), and the associated 
disorder/disease. 
 
Gene  SNP ID PS Domain altered DD Diseases 
ACADS 28940875 Acyl-CoA dehydrogenases signature 2 No SCAD deficiency 
ATP1A2 28934002 E1-E2 ATPases phosphorylation site No 
Alternating hemiplegia of 
childhood 
CPT2 28936375 
Acyltransferases ChoActase / 
COT / CPT family signature 
1 
No Carnitine palmitoyltransferase II deficiency, late-onset 
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CRELD1 28942091 EGF-like domain profile Yes Atrioventricular septal defect, susceptibility to, 2 
CRYGC 28931604 Crystallins beta and gamma 'Greek key' motif profile Yes Cataract, congenital lamellar 
EGFR 28929495 Protein kinases ATP-binding region signature No 
Nonsmall cell lung cancer, 
resistance to tyrosine kinase 
inhibitor in 
ELANE 28931611 Serine proteases, trypsin family, histidine active site No 
Neutropenia, severe congenital, 
autosomal dominant 1 
F11 28934901 Serine proteases, trypsin family, histidine active site No Factor XI deficiency 
FBN1 28929500 EGF-like domain profile Yes Marfan syndrome, subdiagnostic variant of 
FLNA 28935469 Calponin homology domain profile Yes 
Intestinal pseudoobstruction, 
neuronal, chronic idiopathic, X-
linked 
GAA 28940868 Glycosyl hydrolases family 31 signature 2 No Acid alpha-glucosidase, allele 4 
GAA 28937909 Glycosyl hydrolases family 31 signature 2 No Acid alpha-glucosidase, allele 4 
KCNH2 28933095 PAS repeat profile No Long qt syndrome 2 
LGI1 28937874 EAR repeat profile Yes Epilepsy, lateral temporal lobe, autosomal dominant 
LGI1 28939075 EAR repeat profile Yes Epilepsy, lateral temporal lobe, autosomal dominant 
MCFD2 28942114 EF-hand calcium-binding domain profile Yes 
Factor V and Factor VIII, 
combined deficiency of 
MCFD2 28942113 EF-hand calcium-binding domain profile Yes 
Factor V and Factor VIII, 
combined deficiency of 
MPI 28928906 Phosphomannose isomerase type I signature 2 No  
Congenital disorder of 
glycosylation, type IB 
NKX2-1 28936672 Homeobox domain profile Yes Chorea, benign hereditary 
NKX2-1 28936672 Homeobox domain signature No Chorea, benign hereditary 
NOTCH3 28933698 EGF-like domain profile Yes 
Cerebral arteriopathy, 
autosomal dominant, with 
subcortical infarcts and 
leukoencephalopathy 
NOTCH3 28933697 EGF-like domain profile Yes 
Cerebral arteriopathy, 
autosomal dominant, with 
subcortical infarcts and 
leukoencephalopathy 
NOTCH3 28933696 EGF-like domain profile Yes 
Cerebral arteriopathy, 
autosomal dominant, with 
subcortical infarcts and 
leukoencephalopathy 
NOTCH3 28937321 EGF-like domain profile Yes 
Cerebral arteriopathy, 
autosomal dominant, with 
subcortical infarcts and 
leukoencephalopathy 
NPR2 28931582 Natriuretic peptides receptors signature No 
Acromesomelic dysplasia, 
maroteaux type 
PAFAH1B1 28936689 Trp-Asp (WD) repeats profile Yes 
Lissencephaly sequence, 
isolated 
 
 67
RHO 29001653 Visual pigments (opsins) retinal binding site No 
Night blindness, congenital 
stationary, autosomal dominant 
1 
RYR1 28933997 MIR domain profile Yes Central core disease 
SLURP1 28937889 
Prokaryotic membrane 
lipoprotein lipid attachment 
site profile 
No Mal de Meleda 
TMPRSS3 28939084 Serine proteases, trypsin family, serine active site No 
Deafness, congenital 
neurosensory, autosomal 
recessive 10 
TP53 28934575 p53 family signature No Pancreatic cancer 
TP53 28934571 p53 family signature No Pancreatic cancer 
TP53 28934573 p53 family signature No Pancreatic cancer 
TP53 28934572 p53 family signature No Pancreatic cancer 
TP53 11540652 p53 family signature No Pancreatic cancer 
TTR 28933979 Transthyretin signature 1 No Carpal tunnel syndrome, familial 
TYR 28940877 
EGF-like domain signature 
1; Laminin-type EGF-like 
(LE) domain signature 
No Tyrosinase polymorphism 
WT1 28942089 Zinc finger C2H2 type domain profile Yes 
Mesangial sclerosis, isolated 
diffuse 
 
 
Shown in Figure 4.2B is the list of KEGG pathways statistically enriched (p < 
0.01) in proteins with domain-altering SNPs at DD > 0.10. The list contains 
pathways closely associated with cancer, neurological, and immunological 
diseases. Proteins with domain altering SNPs are marked in the pathways for 
focal adhesion and natural killer cell mediated cytotoxicity in Figure 4.3. Nodes 
colored in pink in these figures indicate proteins with domain-altering SNPs, 
while those in blue are their immediate binding partners as identified in HPRD. 
The purple nodes are proteins that belong to both the pink and blue groups. The 
pathway diagrams shown in Figure 4.3 illustrate the presence of proteins with 
domain altering SNPs from the very beginning of the pathway at the cell 
membrane all the way to the transcription factors regulating important cellular 
processes. 
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Next, we estimated the links broken in these pathways due to domain-altering 
SNPs. We have determined domain-domain and domain-motif pairs (signature 
pairs) statistically enhanced in protein-protein interactions involving proteins with 
domain-altering SNPs (Figure 4.4A). The score matrix shown in the figure 
presents the probability of randomly finding a given signature pair along the 
sequences of two binding proteins. The darker a point in the score matrix, the 
higher the association of the signature pair with a protein-protein interaction. In 
this score matrix, we only considered domains with domain-altering SNPs (total 
of 60 on the vertical axis) and their possible interacting partners not abundant in 
the human proteome, meaning they were expressed by less than 25 percent of the 
human proteins. This resulted in a total of 123 counter signatures, composed of 
116 PROSITE domains and 7 ELM motifs on the horizontal axis. The p values for 
signature pair enrichment were computed by comparing the number of signature 
pairs observed in binding interactions of proteins with DA-SNPs in known 
protein-protein interactions (PPIs) with the corresponding number obtained for 
randomly generated virtual PPIs of the same size. The figure shows that only a 
very small fraction of possible signature pairs are statistically enriched in PPIs 
presented in HPRD [26].  
We used statistically enriched signature pairs in the estimates of links broken 
due to a protein expressing a domain-altering SNP. A link (transient or stable) 
between two proteins is assumed broken due to a domain altering SNP if the 
opposing protein pair contains at least one signature enriched with the SNP 
containing domain in the PPIs in HPRD. Shown in Figure 4B is the histogram for 
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proteins with DA-SNPs, thus indicating the number of edges such proteins have 
in the absence of an SNP and the number of edges estimated to be broken due to 
the presence of the SNP. The figure indicates potentially extensive loss of 
connectivity of proteins with DA-SNPs to neighboring proteins in protein 
networks. 
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The protein links we estimate to be broken between a protein containing a DA-
SNP and its immediate neighbors are shown in Figure 4.3A and 4.3B for focal 
adhesion and natural killer cell mediated immunity. The links deemed to be 
broken using the statistical enrichment method described above are shown as 
marked with a circle containing either a red or green “x” or a red “+” sign. The 
links with red “x” correspond to the domain signature pairs present in the 
DOMINE database described as predicting PPIs with high accuracy [27]. The 
links with a green “x” correspond to domain-motif associations deemed highly 
predictive of PPIs [25]. The links marked (+) are links estimated to be broken by 
statistical enrichment of the domain pairs only.   Note that, even when we exclude 
these latter links, the pathway connectivity (number of edges per node) is strongly 
influenced when an SNP drastically alters the 3D shape of a domain responsible 
for connections to upstream and downstream partners. This assertion is further 
enhanced by the list of highly connected proteins with domain altering SNPs 
given in Table 4.3. For example, the transcription factor TCF3 has 44 known 
binding partners, and links to 19 of these partners could be broken due to the 
presence of the domain-altering SNP. Taken together, our study exposes the 
importance of domain SNPs in the progression of some of the most prominent 
complex and/or hereditary diseases.  
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Table 4.3: The top ten most highly connected proteins with domain altering SNPs 
(DD>0.10) and the estimates of the number of broken edges for each protein 
using statistical enrichment .  
 
Gene Protein Name # broken # intact 
ADRBK1 beta-adrenergic receptor kinase 1 29 9 
SH2D1A SH2 domain-containing protein 1A 12 0 
TCF3 transcription factor E2-alpha 19 25 
APBA2 amyloid beta A4 precursor protein-binding family A 8 1 
NCK1 cytoplasmic protein NCK1 61 3 
PRKCH protein kinase C 8 0 
YWHAE 14-3-3 protein epsilon 46 21 
TOPBP1 topoisomerase (DNA) II binding protein 1 11 3 
BCAR1 breast cancer anti-estrogen resistance protein 1 45 3 
RIMS1 regulating synaptic membrane exocytosis protein 1 11 3 
 
 
4.5 Discussion and conclusions 
Recent advances in high throughput sequencing facilitated a number of genome-
wide studies seeking a correlation between genetic makeup and cardiovascular 
diseases [122], autism [123], and diabetes [124]. Results implicate a handful of 
SNPs correlated with these complex disease states. Correlation is based on purely 
statistical methods, and in many cases, SNPs found to be significantly associated 
with a disease fell into the non-coding regions of DNA distant from a protein 
coding gene [69]. As the population subsets for genome-wide studies grow in size 
with increasing research efforts and time, and as these sets are better controlled 
for demographic and environmental variables, one would expect the discovery of 
sets of additional SNPs strongly correlated with hereditary disorders and disease 
subtypes. Nevertheless, a system bioinformatics approach is needed to explore 
how a disease-correlated SNP alters cell signaling and metabolic pathways, thus 
contributing to the initiation of a disorder or a disease.  
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This study explores the mechanisms by which SNPs that fall into protein 
domains in the human genome potentially contribute to disease. Protein domains 
are functional units closely aligned with post-transcriptional modification (as in 
phosphorylation) and play important roles in establishing the connectivity of cell 
signaling networks via binding to upstream and downstream proteins [60, 125]. 
Our computations indicate that the p value for disease association of SNPs that 
fall into protein domains and occur by random chance is practically zero. Within 
this group of SNPs, those with domain-altering properties are even more likely to 
be associated with a disease state. We have defined a domain-altering SNP as one 
that either alters the sequence such that it no longer satisfies the regular 
expression of the domain or that the domain is extensively deformed as quantified 
by the domain distortion index.  Proteins with domain-altering SNPs crowd 
cellular pathways involved in neurological, and immunological diseases, as well 
as in cancers such as the pancreatic cancer.  
How does an SNP with domain altering properties affect the connectivity of 
pathways? The key to answering this question lies in the discovery of the set of 
proteins that bind to proteins under consideration via the domain containing the 
SNP. The grammar of protein-protein interactions in terms of primary sequence 
and/or 3D structure is yet to be fully understood. We used a statistical enrichment 
approach to identify protein domains (motifs) on the opposing protein most 
frequently associated with the SNP-containing domain under consideration.  We 
then assumed a bond (transient or steady) was broken whenever we came across 
such a signature pair among the immediate partners of the protein with a domain 
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altering SNP. Results shown in the present study for focal adhesion and the 
natural killer cell mediated cytotoxicity pathways indicate extensive loss of 
connectivity in these cellular pathways, caused by the presence of domain altering 
SNPs among the proteins in these pathways. Even when we reduced the estimates 
of bonds broken with the use of signature pairs already known to predict protein-
protein interactions, the loss of connectivity persisted at multiple cell 
compartments. We obtained qualitatively similar results for axon guidance and 
neutrophin signaling pathways altered by the presence of a domain altering SNP 
(not shown).  
In conclusion, proteins with domain-altering SNPs are statistically enriched in 
the list of proteins known to be associated with disease. These proteins crowd 
pathways associated with immunological, neurological and cardiomyopathy 
disorders.  Protein functional groups statistically enriched with proteins with 
domain altering SNPs include calcium ion binding, adenyl ribonucleotide binding, 
protein kinase activity, endopeptidase activity, serine-type peptidase activity, 
DNA binding, and GTPase binding proteins 
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CHAPTER 5: FUTURE WORK 
 
5.1 Overview 
Protein-protein interactions (PPIs) are one of the most important categories of 
signal transitions, because the human protein tends to modify the signals via 
protein binding, ion binding and post-translational modifications, rather than 
create new protein sequences [40, 45].   
This dissertation has tried to develop a system that explains the signal 
transduction processes based on built biological functional units. The project tried 
to build a connection between the feature vectors that are related to the protein 
sequence and the biological phenotypes. Large sets of known PPIs (currently over 
38,000 interactions, which are involved with over 9,000 proteins) [43] provide the 
available training data for the machine learning process. In the prediction steps, 
we concentrated on two groups of PPI events, phosphorylation and transcription 
factor activity, instead of focusing on global PPIs. Both groups are significant in 
protein signal processes related to transitional binding and the group either 
contains a specific database (e.g., PTM) or can be filtered by the Gene Ontology 
database from the global protein interaction database. As a result, the most 
informational signal or signal combinations were generated through a score 
matrix model in Chapter 2, and the network of domain-domain interactions (DDIs) 
or domain-motif interactions (DMIs) can be constructed (Figure 5.1). The reason 
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for selecting a group of proteins rather than the global protein set is that the 
binding mechanisms are significantly diverse for different protein types. The 
protein types have to be related to DDIs or DMIs if the feature vectors that are 
applied in the system are protein binding domains/motifs.  
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After defining the most important signals, the functional strings were cross-
validated with independent databases (e.g., PTM 2009 version), 2-fold with 
random protein pairs, and 10-fold with random protein pairs. The results show 
excellent prediction abilities with extremely high specificity.  
 The linkages between the sequence variation parameter (SNPs) to the 
disease/disorder phenotype were built in chapter 4. The mappings were achieved 
by evaluating the alteration that is related to domain/motif grammar signal 
strengths. Currently, there are two categories of methods that are related to SNPs 
and phenotype association predictions. The methods in the first category take the 
defined functional sites, such as phosphorylation sites, and create mappings based 
on the alterations of the critical amino acid. The SNP could disable the unit (e.g., 
phosphorylation site) if it alters the critical site, which affects the biological 
networks. Therefore, the SNPs modified in the functional sites are the potential 
causation/correlation of the diseases. The contribution of these methods is that 
they provide reasonable chain explanations for the SNP-disease associations. The 
problem, however, is that is these methods cannot explain the exceptional cases. 
For example, changes in the critical amino acid do not cause the corresponding 
diseases. The methods in the second category are based on data mining 
technology. The assumption is that the input data are full of errors, and the post-
filtering processes will introduce additional human errors into the system.  As a 
result, the rationale of the methods is to let the data interpret the phenomenon 
without adding any additional information into the system. The accuracy of these 
methods has been proven in many diseases/disorders, such as Parkinson’s 
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diseases. However, the prediction only provides new observations without any 
potential explanations. Chapter 4 has tried to build an SNP-disease association 
model based on the grammars embedded in the protein sequences. The model 
performs as an interface to link the SNPs and phenotypes. As an intermediate 
interface, the model provides the potential explanation of the phenotypes from the 
observations that are related to the grammar alterations. The results showed that 
the disease-related SNPs are highly enriched in the domain regions, and the DA-
SNPs have even better enrichment measurements of the diseases. The “inactive” 
DDIs/DMIs were then projected to the biological networks to identify the broken 
edges. As a result, the model provided a list of DA-SNPs and the functional 
signatures to investigate. The altered functional signatures could be potential drug 
targets in drug development.  
 
5.2 Tag SNPs among different populations 
SNPs occur frequently throughout the human genome. Therefore, they are the 
biomarkers for the human diseases/disorders in the genome-wide association 
study (GWAS) [126]. The International HapMap Project selected four populations 
to include Utah residents with ancestry from northern and western Europe (CEU), 
Han Chinese in Beijing (CHB), Japanese in Tokyo (JPT), and Yoruba in Ibadan 
(YRI). The HapMap project genotyped the individuals among different 
populations and proved that the SNPs for different populations are variant [127]. 
In other words, the variances exist among different populations and the variances 
are the potential causes of different drug responses among different populations.  
The distribution of the SNPs (Figure 5.2), which were generated from the 
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HapMap project raw data, shows that the “global” SNPs only accounted for half 
of all defined SNPs, while about 30% of the SNPs are shared among two or three 
different populations.  
 
  Currently, it is too expensive to genotype all available SNPs across the human 
genome. For diagnostic purposes, a minimum number of SNPs with the most 
accuracy prediction abilities have been selected, called tagSNPs [69]. The 
selections of tagSNPs are based on unsupervised methods with the haplotype 
block concept and the linkage disequilibrium (LD) [128]. The LD describes the 
tendency of alleles to be coinherited in each generation if the alleles are close to 
each other on the same chromosome [128]. In other words, the tagSNPs are the 
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SNPs in the genome with high LD score, which could be coinherited with other 
SNPs. 
TagSNPs are not shared among different populations, either (Figure 5.3). 
TagSNPs that were defined in the HapMap project were projected into the OMIM 
database. 64% of the tagSNPs are common among four populations. About 15% 
of the tagSNPs are unique to one population. Table 5.1 shows some examples of 
tagSNPs related phenotypes that are uniquely expressed among certain 
populations.
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Table 5.1 Examples of population-specific tagSNPs and corresponding 
phenotypes  
 
Population Diseases/Traits description 
CEU SKIN/HAIR/EYE PIGMENTATION 6, BLOND/BROWN HAIR [SLC24A4, G/T] 
  MENTAL RETARDATION, AUTOSOMAL RECESSIVE 10; MRT10 
  NEUROPEPTIDE Y POLYMORPHISM [NPY, LEU7PRO] 
  SKIN/HAIR/EYE PIGMENTATION 3, LIGHT/DARK SKIN [TYR, SER192TYR]  
  CELIAC DISEASE, SUSCEPTIBILITY TO, 13; CELIAC13 
  KIAA1109 GENE; KIAA1109 
  CELIAC DISEASE, SUSCEPTIBILITY TO, 6; CELIAC6 
  PHOSPHODIESTERASE 8B; PDE8B 
  APNEA, POSTANESTHETIC, DUE TO BCHE, ATYPICAL-1 [BCHE, ASP70GLY] 
  HYPOADRENOCORTICISM, FAMILIAL 
  OSTEOARTHRITIS SUSCEPTIBILITY 1 [FRZB, ARG200TRP] 
  DIABETES MELLITUS, INSULIN-DEPENDENT; IDDM 
  NEUROPEPTIDE Y; NPY 
  DIABETES MELLITUS, INSULIN-DEPENDENT, SUSCEPTIBILITY TO [PTPN22, -1123, C-G ] 
  SCHIZOPHRENIA SUSCEPTIBILITY LOCUS, CHROMOSOME 13q-RELATED 
  DISCS LARGE, DROSOPHILA, HOMOLOG OF, 5; DLG5 
  LACTASE PERSISTENCE [MCM6, IVS13, C/T]  
  MENTAL RETARDATION, AUTOSOMAL RECESSIVE 7; MRT7 
  SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 2; SHEP2 
  NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN PROTEIN 2; NOD2 
  LUTEINIZING HORMONE POLYMORPHISM [LHB, TRP8ARG AND ILE15THR]  
  MELANOCORTIN 1 RECEPTOR; MC1R 
  SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 3; SHEP3 
  G30 GENE 
  OBESITY 
  FAT MASS- AND OBESITY-ASSOCIATED GENE; FTO 
  MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 7; CMM7 
CHB CYCLIN-DEPENDENT KINASE INHIBITOR 2B; CDKN2B 
  DIABETES MELLITUS, NONINSULIN-DEPENDENT; NIDDM 
  ANEURYSM, INTRACRANIAL BERRY, 6 
  AORTIC ANEURYSM, FAMILIAL ABDOMINAL 3 
JPT 
Pseudoxanthoma elasticum is an inherited multisystem disorder of the elastic tissue 
leading to skin disease as well as ocular and cardiovascular complications (Struk et 
al., 1997). 
YRI HEMOGLOBIN G (MAKASSAR) [HBB, GLU6ALA] 
  PSEUDOXANTHOMA ELASTICUM; PXE 
  ALCOHOL DEPENDENCE [TAS2R16, LYS172ASN] 
  THYROXINE-BINDING GLOBULIN, SLOW [TBG, ASP171ASN] 
  VASCULAR CELL ADHESION MOLECULE 1; VCAM1  
  HEMOGLOBIN C (GEORGETOWN) [HBB, GLU6VAL AND ASP73ASN] 
  SKIN/HAIR/EYE PIGMENTATION, VARIATION IN, 11; SHEP11 
  GAMMA-AMINOBUTYRIC ACID RECEPTOR, ALPHA-4; GABRA4 
  JUXTAPOSED WITH ANOTHER ZINC FINGER GENE 1; JAZF1 
  HEMOGLOBIN S (CAMEROON) [HBB, GLU6VAL AND GLU90LYS ]  
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  HEMOGLOBIN JAMAICA PLAIN [HBB, GLU6VAL AND LEU68PHE]  
  HEMOGLOBIN S (ANTILLES) [HBB, GLU6VAL AND VAL23ILE]  
  HEMOGLOBIN S (OMAN) [HBB, GLU6VAL AND GLU121LYS]  
  HEMOGLOBIN S (PROVIDENCE) [HBB, GLU6VAL AND LYS82ASX]  
  HEMOGLOBIN S (TRAVIS) [HBB, GLU6VAL AND ALA142VAL]  
  HEPATITIS C VIRUS, RESISTANCE TO [IFNG, -764C-G ]  
  TYROSINASE-RELATED PROTEIN 1; TYRP1 
  GLYCOGEN SYNTHASE KINASE 3-BETA; GSK3B 
  CELIAC DISEASE, SUSCEPTIBILITY TO, 7; CELIAC7 
 
In chapter 4, we proved that the functional signatures (domains/motifs) are 
highly correlated to the disease-related SNPs. Unique tagSNP markers among 
different populations indicate that it is possible to develop a functional signature 
database, not only based on the functions or binding targets of the proteins, but 
also related to the preferences among different populations. In other words, 
focusing on the population-specific sequence biomarkers could lead to the 
development of new domains/motifs for certain population groups.  
 
5.3 Functional signatures in cross-species talk 
Protein-protein interactions occur among different species, such as virus-
infectious processes. The virus proteins have specific targets of certain species. 
For example, the HIV-1 virus infects human individuals, but not mice, rats or 
chickens. However, the sequences are highly similar to each other for different 
eukaryotic organisms. As a result, exploring potential biomarkers for the virus-
specific organisms becomes significant for infection prediction processes. The 
basic assumption is that the functional signature frequencies for the virus and its 
corresponding host organisms should be similar to each other, and different when  
compared to other organisms. 
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Figure 5.4 shows the frequencies for 81 ligand binding motifs from ELM among 
all human protein sequences and hepatitis B virus sequences, which are calculated 
as occurrences per 100 amino acids. The figure shows that although the number of 
proteins is different in the virus and host, the frequencies are similar related to  the 
ligand binding motifs. 
 
 The frequencies of the domains/motifs were then further calculated among five 
different species, including humans, mice, zebra fish, chickens and rats (Figure 
5.5). The functional signatures were combined as one feature vector to compute 
the angle between the virus and different hosts. An example shown in Table 5.2 
indicates the angles of 81 ligand binding motifs among humans and four types of 
virus (hepatitis A, B, C and HIV-1). The “+” sign indicates the large variation 
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(motif expression is different). Based on these primary results, it is possible to 
develop a model to select species-specific biomarkers from functional signatures. 
  
Table 5.2 Angles of ELM ligand binding motif vectors across species 
The table contains the angles between species (human, hepatitis A, B, C and HIV-
1), calculated based on ligand binding vectors. “+” indicates the significant of 
motif frequencies. 
 
  HepA_human HepB_human HepC_human HIV_1 
LIG_14-3-3_1 0 0 0 0 
LIG_14-3-3_2 0 + 0 0 
LIG_14-3-3_3 + + + + 
LIG_AP2alpha_1 0 0 0 0 
LIG_AP2alpha_2 0 0 0 0 
LIG_AP_GAE_1 0 0 0 0 
LIG_APCC_Dbox_1 + + + + 
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LIG_APCC_KENbox_2 0 0 0 0 
LIG_BRCT_BRCA1_1 + + + + 
LIG_BRCT_BRCA1_2 0 0 + 0 
LIG_BRCT_MDC1_1 0 0 0 + 
LIG_CAP-Gly_1 0 0 0 0 
LIG_Clathr_ClatBox_1 0 + + + 
LIG_Clathr_ClatBox_2 0 0 0 0 
LIG_COP1 0 0 0 0 
LIG_CORNRBOX 0 0 0 0 
LIG_CtBP + 0 0 0 
LIG_CYCLIN_1 + + + + 
LIG_Dynein_DLC8_1 0 0 0 0 
LIG_EH 0 0 0 0 
LIG_EH1 0 0 + + 
LIG_EVH1_I + 0 0 + 
LIG_EVH1_II 0 0 0 0 
LIG_FHA_1 + + + + 
LIG_FHA_2 + + + + 
LIG_GYF 0 0 0 0 
LIG_HOMEOBOX 0 0 0 0 
LIG_HP1_1 0 0 0 0 
LIG_IBS_1 0 0 0 0 
LIG_IQ + 0 0 + 
LIG_MAD2 0 0 0 0 
LIG_MAPK_1 + + + + 
LIG_MAPK_2 + 0 0 + 
LIG_MDM2 0 + + 0 
LIG_MYND 0 0 0 0 
LIG_NRBOX + + + + 
LIG_PCNA 0 0 0 0 
LIG_PDZ_1 0 0 0 0 
LIG_PDZ_2 0 + 0 0 
LIG_PDZ_3 + + + + 
LIG_PIP2_ANTH_1 0 0 0 0 
LIG_PIP2_ENTH_1 0 0 0 0 
LIG_PP1 + + + + 
LIG_PP2B_1 0 0 0 + 
LIG_PTAP 0 0 0 + 
LIG_PTB_1 0 0 0 0 
LIG_PTB_2 0 0 0 0 
LIG_PXL 0 0 0 0 
LIG_RB 0 0 + + 
LIG_RGD 0 0 + 0 
LIG_RRM_PRI_1 0 + 0 0 
LIG_SH2_GRB2 + + + 0 
LIG_SH2_PTP2 0 + + + 
LIG_SH2_SRC + + + + 
LIG_SH2_STAT3 + 0 + + 
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LIG_SH2_STAT5 + + + + 
LIG_SH2_STAT6 0 0 0 0 
LIG_SH3_1 0 + + + 
LIG_SH3_2 0 + + + 
LIG_SH3_3 + + + + 
LIG_SH3_4 0 0 + + 
LIG_SH3_5 0 + 0 + 
LIG_SIAH_1 0 0 0 0 
LIG_Sin3_1 0 0 0 0 
LIG_Sin3_2 0 0 0 0 
LIG_Sin3_3 0 0 0 0 
LIG_TNKBM 0 0 0 0 
LIG_TPR 0 0 0 0 
LIG_TRAF2_1 + + + + 
LIG_TRAF2_2 0 0 0 0 
LIG_TRAF6 + 0 + + 
LIG_ULM_U2AF65_1 0 0 0 + 
LIG_USP7_1 + + + + 
LIG_USP7_2 + 0 + 0 
LIG_WH1 0 0 0 0 
LIG_WRPW_1 0 0 0 0 
LIG_WRPW_2 0 0 0 0 
LIG_WW_1 0 0 0 0 
LIG_WW_2 0 0 0 + 
LIG_WW_3 + 0 + 0 
LIG_WW_4 + + + + 
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APPENDICES 
 
Appendix A: PROSITE domains that are statistically enriched in subtypes of 
kinases and substrates. Columns of the table represent domain index used in 
Figure 2.1B, domain name, domain PROSITE ID Number as well as the kinase 
groups for which the domain is enriched.  
http://code.google.com/p/tozerenlab/downloads/list 
 
 
Appendix B: The list of domain-strings pairs used in predicting phosphorylation 
PPI with high specificity (SP > 0.91). DSIK: Domain string index for the kinase 
in PPI; DSIS: Domain string index for the substrate in PPI. 
http://code.google.com/p/tozerenlab/downloads/list 
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